Document:

Execution
Version

 

EMPLOYEE
MATTERS AGREEMENT

 

by
and between

 

BIOTIME,
INC.

 

and

 

AGEX
THERAPEUTICS, INC.

 

Dated
as of August 17, 2017

 

    	 

    	 

    

 

Execution Version

 

TABLE
OF CONTENTS 

 

	ARTICLE 1 – Definitions and Interpretation 	1
	 	 	 
	1.1	Definitions	1
	1.2	References;
    Interpretation	4
	 	 	 
	ARTICLE 2 – General Principles 	4
	 	 	 
	2.1	Nature
    of Liabilities	4
	2.2	Employee
    Transfers Generally	4
	2.3	Assumption
    and Retention of Liabilities Generally	5
	2.4	AgeX
    Participation in BioTime Benefit Plans	6
	2.5	Comparable
    Compensation and Benefits	6
	2.6	Service
    Recognition	6
	2.7	AgeX
    Stock Plan	7
	2.8	Time-Off
    Benefits	7
	2.9	Shared
    Facilities and Services Agreement	7
	2.10	Special
    Workers’ Compensation Considerations	7
	 	 	 
	ARTICLE 3 – Certain U.S. Benefit Plan Provisions 	8
	 	 	 
	3.1	U.S.
    Savings Plan	8
	3.2	U.S.
    OPEB/COBRA	8
	3.3	U.S.
    Active Employee Welfare Benefits	8
	3.4	Annual
    Incentive Awards	9
	 	 	 
	ARTICLE 4 – Equity Incentive Awards 	9
	 	 	 
	4.1	Treatment
    of BioTime Options and BioTime Stock Appreciation Rights	9
	4.2	General	10
	 	 	 
	ARTICLE 5 – General and Administrative 	10
	 	 	 
	5.1	Employer
    Rights	10
	5.2	Effect
    on Employment	10
	5.3	Non-Solicitation
    Provisions	11
	5.4	Sections
    162(m)/409A	11
	5.5	Access
    to Employees	11
	 	 	 
	ARTICLE 6 – Miscellaneous 	12
	 	 	 
	6.1	Complete
    Agreement; Construction	12
	6.2	Counterparts	12
	6.3	Waivers	12
	6.4	Assignment	12
	6.5	Successors
    and Assigns	12
	6.6	Termination
    and Amendment	12
	6.7	Subsidiaries	13
	6.8	Third
    Party Beneficiaries	13
	6.9	Title
    and Headings	13
	6.10	Exhibits
    and Schedules	13
	6.11	Governing
    Law	13
	6.12	Severability	14
	6.13	Interpretation	14
	6.14	No
    Duplication; No Double Recovery	14
	6.15	Notices	14

 

    	i

    	 

    

 

Execution
Version

 

EMPLOYEE
MATTERS AGREEMENT

 

This
EMPLOYEE MATTERS AGREEMENT (this “Agreement”), dated as of August 17, 2017, is entered into by and between
BioTime, Inc. (“BioTime”), a California corporation, and AgeX Therapeutics, Inc. (“AgeX”),
a Delaware corporation and a wholly owned subsidiary of BioTime. “Party” or “Parties” means
BioTime or AgeX, individually or collectively, as the case may be.

 

W
I T N E S S E T H:

 

WHEREAS,
BioTime, acting directly or through its direct and indirect Subsidiaries, currently conducts the BioTime Retained Business and
the AgeX Business;

 

WHEREAS,
the BioTime Board has determined that it is appropriate, desirable and in the best interests of BioTime and its shareholders to
organize and separately finance a new subsidiary, AgeX Therapeutics, Inc., to continue to pursue certain BioTime research and
development programs that have not yet advanced to the point of clinical development;

 

WHEREAS,
the Parties have entered into an Asset Contribution and Separation Agreement, dated as of August 17, 2017 (the “ACA”);
and

 

WHEREAS,
the ACA provides that the Parties will enter into this Employee Matters Agreement to document certain agreements and arrangements
in connection with the contribution of assets to the AgeX Group and the separation of the AgeX Business from the BioTime Group
through the Distribution.

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual agreements, provisions and covenants contained in this Agreement,
the Parties hereby agree as follows:

 

ARTICLE
1

DEFINITIONS
AND INTERPRETATION

 

1.1
Definitions. Capitalized terms used but not defined in this Agreement shall have the meanings ascribed to such terms in the
ACA. The following terms shall have the following meanings:

 

“Agreement”
shall have the meaning set forth in the Preamble.

 

“Benefit
Plan” shall mean, with respect to any BioTime Group Member or AgeX Group Member, each plan, program, arrangement, agreement
or commitment that is an employment, consulting, non-competition or deferred compensation agreement, or an executive compensation,
bonus, employee pension, profit-sharing, savings, retirement, stock option, stock purchase, stock appreciation right, restricted
stock, other equity-based compensation plan, or life, health, hospitalization, disability or accident insurance plan, corporate-owned
or key-man life insurance or other employee benefit plan, program, arrangement, agreement or commitment, including any “employee
benefit plan” (as defined in Section 3(3) of ERISA), sponsored or maintained by such entity (or to which such entity contributes
or is required to contribute).

 

    	1

    	 

    

 

“Bonus
Programs” shall have the meaning set forth in Section 3.4.

 

“AgeX”
shall have the meaning set forth in the Preamble.

 

“AgeX
401(k) Plan” shall have the meaning set forth in Section 3.1.

 

“AgeX
Benefit Plan” shall mean any Benefit Plan sponsored, maintained or contributed to by any AgeX Group Member or any ERISA
Affiliate thereof at the Closing Date or the Distribution Date.

 

“AgeX
Group Employee” shall mean an active employee or an employee on approved leave of absence (including maternity, paternity,
family, sick leave, qualified military service under the Uniformed Services Employment and Reemployment Rights Act of 1994, and
leave under the Family Medical Leave Act and other approved leaves) who, on the Closing Date or the Distribution Date, is employed
by any AgeX Group Member.

 

“AgeX
Option” shall have the meaning set forth in Section 4.1(a).

 

“AgeX
RSU” shall have the meaning set forth in Section 4.1(a).

 

“AgeX
SAR” shall have the meaning set forth in Section 4.1(a).

 

“AgeX
Stock Plan” shall have the meaning set forth in Section 2.7.

 

“AgeX
Welfare Plans” shall mean those welfare benefit plans (including each “welfare benefit plan” within the
meaning of Section 3(1) of ERISA) established or maintained by any AgeX Group Member on or after the Closing Date.

 

“Benefit
Plan” shall mean, with respect to an BioTime Group Member or AgeX Group Member, each plan, program, arrangement, agreement
or commitment that is an employment, consulting, non-competition or deferred compensation agreement, or an executive compensation,
bonus, employee pension, profit-sharing, savings, retirement, supplemental retirement, stock option, stock purchase, stock appreciation
rights, restricted stock, other equity-based compensation, life, health, hospitalization, disability or accident insurance plan
or agreement, corporate-owned or key-man life insurance or other employee benefit plan, program, arrangement, agreement or commitment,
including any “employee benefit plan” (as defined in Section 3(3) of ERISA), sponsored or maintained by such BioTime
Group Member or AgeX Group Member (or to which such companies contributes or is required to contribute).

 

“BioTime”
shall have the meaning set forth in the Preamble.

 

“BioTime
401(k) Plan” shall mean the Retirement Savings Plan of BioTime.

 

    	2

    	 

    

 

“BioTime
Benefit Plan” shall mean any Benefit Plan sponsored, maintained or contributed to by any BioTime Group Member or any
ERISA Affiliate thereof at the Closing Date or Distribution Date.

 

“BioTime
Equity Plan” shall mean the BioTime Equity Incentive Plan, as amended, for employees, officers, non-employee directors
or independent contractors of BioTime or its Affiliates.

 

“BioTime
Group Employee” shall mean an active employee or an employee on vacation or on approved leave of absence (including
maternity, paternity, family, sick leave, qualified military service under the Uniformed Services Employment and Reemployment
Rights Act of 1994, and leave under the Family Medical Leave Act and other approved leaves) who, immediately after the Closing
Date or on the Distribution Date, is employed by any BioTime Group Member.

 

“BioTime
Option” shall mean an option to purchase BioTime common shares granted pursuant to one of the BioTime Stock Plans.

 

“BioTime
Restricted Stock Unit” shall mean a unit pursuant to the BioTime Incentive Plan representing a general unsecured promise
by BioTime to deliver a BioTime common share and dividend equivalents, if applicable (or the cash equivalent of either), upon
the satisfaction of a vesting requirement.

 

“BioTime
Stock Appreciation Right” shall mean a stock appreciation right granted pursuant to the BioTime Equity Plan.

 

“BioTime
2002 Plan” shall mean the BioTime 2002 Stock Option Plan, as amended, for employees, officers, non-employee directors
or independent contractors of BioTime or its Affiliates.

 

“BioTime
Stock Plan” shall mean the BioTime Equity Plan or the BioTime 2002 Plan.

 

“BioTime
Welfare Plans” shall mean those welfare benefit plans (including each “welfare benefit plan” within the
meaning of Section 3(1) of ERISA) maintained by any BioTime Group Member in respect of BioTime Group Employees or AgeX Group Employees
at the Closing Date or the Distribution Date.

 

“ERISA”
shall mean the Employee Retirement Income Security Act of 1974, as amended.

 

“ERISA
Affiliate” shall mean with respect to any Person, each business or entity which is a member of a “controlled group
of corporations,” under “common control” or a member of an “affiliated service group” with such
Person within the meaning of Sections 414(b), (c) or (m) of the Code, or required to be aggregated with such Person under Section
414(o) of the Code, or under “common control” with such Person within the meaning of Section 4001(a)(14) of ERISA.

 

    	3

    	 

    

 

“Former
Employee” shall mean any individual who was employed before the Closing Date by a BioTime Group Member or AgeX Group
Member but who, as of the Closing Date or Distribution Date, is not employed by a BioTime Group Member or AgeX Group Member.

 

“Liabilities”
shall have the meaning set forth in the ACA, modified so as to disregard for these purposes the last sentence thereof and
to expressly include Taxes as Liabilities.

 

“Parties”
shall have the meaning set forth in the Preamble.

 

“Performance
Period” shall have the meaning set forth in Section 3.4.

 

“Prior
Period Bonuses” shall have the meaning set forth in Section 3.4.

 

“ACA”
shall have the meaning set forth in the Recitals.

 

1.2
References; Interpretation. References in this Agreement to any gender include references to all genders, and references to
the singular include references to the plural and vice versa. Unless the context otherwise requires, the words “include”,
“includes” and “including” when used in this Agreement shall be deemed to be followed by the phrase “without
limitation”. Unless the context otherwise requires, references in this Agreement to Articles, Sections, Exhibits and Schedules
shall be deemed references to Articles and Sections of, and Exhibits and Schedules to, this Agreement. Unless the context otherwise
requires, the words “hereof”, “hereby” and “herein” and words of similar meaning when used
in this Agreement refer to this Agreement in its entirety and not to any particular Article, Section or provision of this Agreement.
The words “written request” when used in this Agreement shall include email. Reference in this Agreement to any time
shall be to California time unless otherwise expressly provided herein.

 

ARTICLE
2

GENERAL
PRINCIPLES

 

2.1
Nature of Liabilities. All Liabilities assumed or retained by the BioTime Group under this Agreement shall be BioTime Retained
Liabilities for purposes of the ACA. All Liabilities assumed or retained by the AgeX Group under this Agreement shall be AgeX
Liabilities for purposes of the ACA.

 

2.2
Employee Transfers Generally. BioTime shall prepare and maintain a schedule of employees who are designated as BioTime Group
Employees, and a schedule of employees who are designated as AgeX Group Employees. Subject to the applicable Legal Requirements,
through and until immediately before the Distribution Date, BioTime may cause the employment of any employee of any BioTime Group
Member to be transferred to any AgeX Group Member, whereupon such employee shall become an AgeX Group Employee, and BioTime may
cause the employment of any employee of any AgeX Group Member to be transferred to any BioTime Group Member, whereupon such employee
shall become a BioTime Group Employee.

 

    	4

    	 

    

 

2.3
Assumption and Retention of Liabilities Generally.

 

(a)
On and after the Closing Date, except as otherwise expressly provided for in this Agreement, BioTime shall, or shall cause one
or more BioTime Group Members to, assume or retain and BioTime hereby agrees to (or to cause a BioTime Group Member to) pay, perform,
fulfill and discharge, in due course in full (i) all Liabilities under all BioTime Benefit Plans arising prior to the Closing
Date, (ii) all Liabilities (excluding Liabilities incurred under a BioTime Benefit Plan) with respect to the employment, service,
termination of employment or termination of service of all BioTime Group Employees and Former Employees to the extent arising
in connection with or as a result of employment with or the performance of services for any BioTime Group Member before, on or
after the Closing Date and (iii) all Liabilities (excluding Liabilities incurred under a BioTime Benefit Plan) with respect to
the employment, service, termination of employment or termination of service of all BioTime Group Employees and Former Employees
to the extent arising in connection with or as a result of employment with or the performance of services for any AgeX Group Member
before the Closing Date, and (iv) any other Liabilities or obligations expressly assigned to BioTime Group Members under this
Agreement.

 

(b)
On and after the Closing Date, except as otherwise expressly provided for in this Agreement, AgeX shall, or shall cause one or
more AgeX Group Members to, assume or retain, as applicable, and AgeX hereby agrees to (or to cause an AgeX Group Member to) pay,
perform, fulfill and discharge, in due course in full (i) all Liabilities under all AgeX Benefit Plans, (ii) all Liabilities with
respect to the employment, service, termination of employment or termination of service of all AgeX Group Employees to the extent
arising in connection with or as a result of employment with or the performance of services for any BioTime Group Member or AgeX
Group Member on or after the Closing Date and (iii) any other Liabilities or obligations expressly assigned to any AgeX Group
Member under this Agreement.

 

(c)
AgeX Group employees may participate in certain BioTime Benefit Plans while AgeX remains a subsidiary of BioTime or while BioTime
holds a substantial equity interest in AgeX. AgeX agrees to reimburse BioTime promptly after receipt of an invoice for costs incurred
by BioTime on account of AgeX Group employees under or in connection with any BioTime Benefit Plan on or after the Closing Date,
except to the extent that all or a portion of such benefits are expressly allocated to any BioTime Group Member rather than to
AgeX or any AgeX Group Member under an employment agreement with any BioTime Group Member.

 

(d)
From time to time after the Closing Date, AgeX shall promptly reimburse BioTime, upon BioTime’s reasonable request and the
presentation by BioTime of such substantiating documentation as AgeX shall reasonably request, for the cost of any obligations
or Liabilities satisfied or assumed by BioTime or any BioTime Group Member that are, or that have been made pursuant to this Agreement,
the responsibility of AgeX or any AgeX Group Member.

 

(e)
From time to time after the Closing Date, BioTime shall promptly reimburse AgeX, upon AgeX’ reasonable request and the presentation
by AgeX of such substantiating documentation as BioTime shall reasonably request, for the cost of any obligations or Liabilities
satisfied or assumed by AgeX or any AgeX Group Member that are, or that have been made pursuant to this Agreement, the responsibility
of BioTime or any BioTime Group Member.

 

    	5

    	 

    

 

2.4
AgeX Participation in BioTime Benefit Plans.

 

(a)
During the period beginning on the Closing Date and preceding the Distribution Date, the AgeX Group Employees shall be eligible
to participate in the Benefit Plans maintained by the BioTime Group on such basis as shall be determined by BioTime from time
to time. Without limiting Section 2.3(b)(ii), AgeX shall, or shall cause one or more AgeX Group Members to, assume or retain,
as applicable, and AgeX hereby agrees to (or to cause an AgeX Group Member to) pay, perform, fulfill and discharge, in due course
in full all Liabilities attributable to AgeX Group Employees in respect of such participation in accordance with BioTime’s
historical cost allocation practices, or shall, upon request, reimburse BioTime in full for all costs and expenses incurred by
BioTime or any BioTime Group Member on account of such Benefit Plan Liabilities.

 

(b)
Except as otherwise expressly provided in this Agreement, effective as of the Distribution Date: (i) each AgeX Group Member shall
cease to be a participating company in any BioTime Benefit Plan; and (ii) except as required by applicable Legal Requirements,
each AgeX Group Employee shall cease to participate in, be covered by, accrue benefits under, be eligible to contribute to or
have any rights under any BioTime Benefit Plan.

 

2.5
Comparable Compensation and Benefits. From the Closing Date until the Distribution Date, AgeX (acting directly or through
AgeX Group Member) shall provide each AgeX Group Employee with compensation (including base pay and incentive compensation opportunities,
severance compensation and paid time off) no less favorable and with employee benefits (exclusive of post-retirement welfare benefits
and defined benefit pension benefits) comparable in the aggregate to, respectively, the compensation and employee benefits to
which the AgeX Group Employee was entitled while employed by a BioTime Group Member or AgeX Group Member immediately prior to
the Distribution Date. .

 

2.6
Service Recognition.

 

(a)
For purposes of eligibility, vesting, determination of level of benefits, and, to the extent applicable, benefit accruals under
any employee compensation or Benefit Plan that an AgeX Group Member shall establish or maintain on or after the Closing Date,
AgeX shall cause each AgeX Group Employee to receive full credit for the AgeX Group Employee’s service with any BioTime
Group Member before the Closing Date to the same extent such service was recognized by an analogous BioTime Benefit Plan immediately
before the Closing Date; provided, that such service shall not be recognized to the extent that such recognition would
result in the duplication of benefits.

 

(b)
Except to the extent prohibited by applicable Legal Requirements or not practicable using commercially reasonable efforts: (i)
AgeX shall waive or cause to be waived all limitations as to preexisting conditions or waiting periods with respect to participation
and coverage requirements applicable to each AgeX Group Employee under any Benefit Plans, programs and policies of any AgeX Group
Member in which AgeX Group Employees participate (or are eligible to participate) that are “welfare benefit plans”
(as defined in Section 3(1) of ERISA) to the same extent that such conditions and waiting periods were satisfied or waived under
an analogous BioTime Benefit Plan immediately before the Closing Date, and (ii) AgeX shall provide or cause each AgeX Group Employee
to be provided with credit for any co-payments (other than co-payments not reimbursable to an employee under the corresponding
BioTime Benefit Plan) and deductibles paid during the plan year in which the Distribution Date occurs in satisfying any applicable
co-payments, deductibles or other out-of-pocket requirements under any such welfare benefit plans for such plan year.

 

    	6

    	 

    

 

2.7
AgeX Stock Plan. Effective as of the Closing Date, AgeX shall have adopted the AgeX Equity Incentive Plan (the “AgeX
Stock Plan”), which shall permit the issuance of equity incentive awards denominated in AgeX Common Stock. The AgeX
Stock Plan shall be approved within one year after its adoption by the AgeX Board by BioTime as AgeX’s majority shareholder.

 

2.8
Time-Off Benefits. AgeX shall credit each AgeX Group Employee with the amount of accrued but unused vacation time and other
time-off benefits as such AgeX Group Employee had with the BioTime Group as of immediately before the Closing Date; provided,
that AgeX shall reimburse BioTime promptly upon request for any payments made or required to be made under applicable Legal Requirements
by any BioTime Group Member to any AgeX Group Employee (including also any Former Employee who was an AgeX Group Employee) on
account of accrued but unused vacation or other time-off benefits.

 

2.9
Shared Facilities and Services Agreement. Notwithstanding any allocation of employees between the BioTime Group and AgeX Group,
and the allocation of Liabilities between the BioTime Group and AgeX Group pursuant to this Article 2, BioTime Group Employees
may provide services to the AgeX Group and AgeX Group Employees may provide services to the BioTime Group pursuant to the Shared
Facilities and Services Agreement, and the fees applicable to such services shall be paid as provided in the Shared Facilities
and Services Agreement. For the avoidance of doubt, in the event of any conflict between allocations of costs for services of
employees under the Shared Facilities Agreement and allocations of Liabilities under any other Section of this Article 2, the
provisions of the Shared Facilities and Services Agreement shall control.

 

2.10
Special Workers’ Compensation Considerations. Without limiting Section 2.3(b), AgeX shall, or shall cause one or more
AgeX Group Members to, assume or retain, as applicable, on and after the Closing Date, all Liabilities in the nature of or similar
to workers’ compensation obligations in respect of (a) AgeX Group Employees, (b) Former Employees who terminated employment
with the BioTime Group and AgeX Group before the Closing Date and whose employment at the time of termination was primarily in
respect of the AgeX Business, (c) current or former independent contractors of the BioTime Group or AgeX Group whose services
are or were primarily in respect of the AgeX Business, and (d) to the extent relating to claims of employees and independent contractors
set forth on a Schedule to the ACA and designated as an AgeX Liability or BioTime Assumed Liability under the ACA.

 

    	7

    	 

    

 

ARTICLE
3

CERTAIN
U.S. BENEFIT PLAN PROVISIONS

 

3.1
401(k) Plan. Effective as of the Distribution Date, BioTime shall retain and be solely responsible for all Liabilities and
obligations with respect to AgeX Group Employees under the BioTime 401(k) Plan as of the Distribution Date. As soon as practicable
after the Distribution Date, the BioTime 401(k) Plan shall, to the extent permitted by Section 401(k)(2)(B)(i)(I) of the Code,
make cash distributions (but including promissory notes representing participant loans) available to AgeX Group Employees who
participate in the BioTime 401(k) Plan. AgeX shall (or shall cause an AgeX Group Member to) establish or maintain a defined contribution
plan and trust intended to qualify under Section 401(a) and Section 501(a) of the Code (the “AgeX 401(k) Plan”)
that shall accept a contribution in cash or, to the extent of any promissory notes representing participant loans, in kind, attributable
to any eligible rollover distribution (within the meaning of Section 401(a)(31) of the Code) of the benefit of a AgeX Group Employee
under the BioTime 401(k) Plan; provided, that the obligation to accept such a rollover in kind shall expire twelve (12) months
after the Distribution Date. The Parties agree to cooperate so as not to place any loan with respect to a AgeX Group Employee’s
account under the BioTime 401(k) Plan into default during the period from the Distribution Date until the rollover is completed;
provided, that such employee continues making loan repayments on a timely basis during such period in accordance with the BioTime
401(k) Plan’s procedures.

 

3.2
U.S. OPEB/COBRA. BioTime shall (or shall cause a BioTime Group Member to) retain and be solely responsible for all Liabilities
and obligations with respect to AgeX Group Employees under each post-retirement welfare benefit plan maintained by any BioTime
Group Member primarily for the benefit of employees in the United States. Any such benefit plan shall be a secondary payer in
regard to any Benefit Plan maintained by any AgeX Group Member for active employees.

 

3.3
U.S. Active Employee Welfare Benefits.

 

(a)
Insured Benefits. With respect to employee welfare and fringe benefits that are provided through the purchase of insurance,
BioTime shall cause the BioTime Welfare Plans to fully perform, pay and discharge all claims of AgeX Group Employees that are
incurred prior to the Distribution Date (subject to the second sentence of Section 2.4(a)) and AgeX shall cause the AgeX Welfare
Plans to fully perform, pay and discharge all claims of AgeX Group Employees that are incurred on or after the Distribution Date.

 

(b)
Self-Insured Benefits. With respect to employee welfare and fringe benefits that are provided on a self-insured basis,
(A) subject to the second sentence of Section 2.4(a), BioTime (acting directly or through BioTime Group Members) shall fully perform,
pay and discharge, under the BioTime Welfare Plans, all claims of AgeX Group Employees that are incurred but not paid prior to
the Distribution Date, and (B) AgeX (acting directly or through AgeX Group Members) shall fully perform, pay and discharge, under
the AgeX Welfare Plans, from and after the Distribution Date, all claims of AgeX Group Employees that are incurred on or after
the Distribution Date. For purposes of this Section 3.3(b), a claim is deemed to be incurred (i) with respect to medical, dental,
vision and/or prescription drug benefits, upon the rendering of health services giving rise to such claim; (ii) with respect to
life insurance, accidental death and dismemberment and business travel accident insurance, upon the occurrence of the event giving
rise to such claim; (iii) with respect to disability benefits, upon the date of an individual’s disability, as determined
by the disability benefit insurance carrier or claim administrator, giving rise to such claim; and (iv) with respect to a period
of continuous hospitalization, upon the date of admission to the hospital.

 

    	8

    	 

    

 

3.4
Annual Incentive Awards. Subject to the second sentence of Section 2.4(a), no AgeX Group Member shall assume or be responsible
for any Liabilities in relation to any non-equity incentive compensation programs maintained in respect of AgeX Group Employees
(“Bonus Programs”) to the extent such Liabilities relate to any annual, quarterly or other temporal period (any such
period, a “Performance Period”) that has ended prior to the year in which the Closing Date occurs (a “Prior
Period Bonuses”) and, to the extent not yet paid prior to the date of this Agreement, BioTime or another BioTime Group Member
shall be solely responsible for and shall pay all Liabilities in relation to Prior Period Bonuses as such Liabilities fall due
and as determined in a manner consistent with historical practice. With respect to any Performance Period that has not yet ended
on, or begins on or after, the first day of the calendar year in which the Closing Date occurs, BioTime and AgeX shall mutually
determine the amount of any bonuses payable under the Bonus Programs and how such bonus payments will be allocated between and
paid by BioTime and AgeX; provided, that either party may unilaterally elect to award bonuses for such period to such employees
and in such amounts as it determines, but a party making any such unilateral award shall not be entitled to reimbursement from
the other party for any portion of the bonus so awarded.

 

ARTICLE
4

EQUITY
INCENTIVE AWARDS

 

4.1
Treatment of BioTime Options, BioTime RSUs and BioTime SARs .

 

(a)
Each BioTime Option, BioTime restricted stock unit (“BioTime RSU”), or BioTime stock appreciation right (“BioTime
SAR”) that is outstanding immediately before the Closing Date shall not be affected by the termination of the employment
of the employee who holds such BioTime Option, BioTime RSU, or BioTime SAR by any BioTime Group Member and the concurrent employment
of such employee by any AgeX Group Member on or immediately after the Closing Date. On or before the Distribution Date, BioTime
and AgeX shall determine whether BioTime Options, BioTime RSUs, and BioTime SARs held by an AgeX Group Employee on the Distribution
Date shall be cancelled and replaced with an option to purchase AgeX Common Stock (a “AgeX Option”), or AgeX
restricted stock unit (“AgeX RSU”), or AgeX stock appreciation right (“AgeX SAR”). The terms of any AgeX
Option, AgeX RSU , or AgeX SAR issued in replacement of any BioTime Option, BioTime RSU, or BioTime SAR shall be determined by
the AgeX Board in its discretion provided, that, without limiting Section 2.6, with respect to each AgeX Option, AgeX RSU, or
AgeX SAR issued in replacement of any BioTime Option, BioTime RSU, or BioTime SAR AgeX shall give each AgeX Group Employee full
vesting service credit for such AgeX Group Employee’s service with any BioTime Group Member before the Distribution Date
to the same extent such service was recognized with respect to the corresponding BioTime Option or BioTime RSU immediately before
the Distribution Date. The BioTime Board or its Compensation Committee shall determine whether any BioTime Option, BioTime RSU,
or BioTime SAR that is not cancelled and replaced by an AgeX Option, AgeX RSU, or AgeX SAR shall be amended in any way that benefits
the holder thereof.

 

    	9

    	 

    

 

(b)
The exercise of each AgeX Option and settlement of each AgeX RSU or AgeX SAR shall be subject to the terms of the AgeX Stock Plan.

 

4.2
General.

 

(a)
All of the adjustments described in this Article 4 shall be effected in accordance with Sections 424 and 409A of the Code.

 

(b)
The Parties shall use commercially reasonable efforts to maintain effective registration statements with the SEC with respect
to the awards described in this Article 4, to the extent any such registration statement is required by the Securities Act.

 

(c)
The Parties hereby acknowledge that the provisions of this Article 4 are intended to achieve certain tax, legal and accounting
objectives and, in the event such objectives are not achieved, the Parties agree to negotiate in good faith regarding such other
actions that may be necessary or appropriate to achieve such objectives.

 

ARTICLE
5

GENERAL
AND ADMINISTRATIVE

 

5.1
Employer Rights. Nothing in this Agreement shall be deemed to be an amendment to any BioTime Benefit Plan or AgeX Benefit
Plan or to prohibit any BioTime Group Member or AgeX Group Member, as the case may be, from amending, modifying or terminating
any BioTime Benefit Plan or AgeX Benefit Plan at any time within its sole discretion.

 

5.2
Effect on Employment. Nothing in this Agreement is intended to or shall confer upon any BioTime Group Employee, AgeX Group
Employee, or Former Employee any right to continued employment, or any recall or similar rights to any such individual on layoff
or any type of approved leave.

 

    	10

    	 

    

 

5.3
Non-Solicitation Provisions. For a period of three (3) years from the Distribution Date: (a) neither BioTime nor any BioTime
Group Member shall, without the prior written consent of AgeX, directly or indirectly, solicit for employment or hire (whether
as an employee, consultant or otherwise) any individual who at the Distribution Date is an employee of any AgeX Group Member,
or induce, or attempt to induce, any such employee to terminate his or her employment with, or otherwise cease his or her relationship
with, an AgeX Group Member; and (b) neither AgeX nor any AgeX Group Member shall, without the prior written consent of BioTime,
directly or indirectly, solicit for employment or hire (whether as an employee, consultant or otherwise) any individual who at
the Distribution Date is an employee of any BioTime Group Member, or induce, or attempt to induce, any such employee to terminate
his or her employment with, or otherwise cease his or her relationship with, a BioTime Group Member; provided, that nothing
in this Section 5.3 shall be deemed to prohibit any general solicitation for employment through advertisements and search firms
not specifically directed at employees of the BioTime Group Members or AgeX Group Members, as applicable; and provided, further
that if during the three-year period following the Distribution Date, AgeX or any AgeX Group Member hires any individual who at
the Distribution Date was an employee of any BioTime Group Member outside of the United States, whether in violation of this Section
5.3 (determined without regard to its enforceability) or otherwise, AgeX shall upon demand from BioTime promptly reimburse BioTime
for any severance and retirement costs incurred by any BioTime Group Member in respect of the termination of such individual’s
employment from the BioTime Group Member. The Parties agree that irreparable damage would occur in the event that the provisions
of this Section 5.3 were not performed in accordance with their specific terms. Accordingly, it is hereby agreed that the Parties
shall be entitled to an injunction or injunctions to enforce specifically the terms and provisions of this Section 5.3 in any
court of the United States or in the courts of any state having jurisdiction, or in the courts of any other country or locality
thereof having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity.

 

5.4
Sections 162(m)/409A. Notwithstanding anything in this Agreement to the contrary (including the treatment of supplemental
and deferred compensation plans, outstanding long-term incentive awards and annual incentive awards as described herein), the
Parties agree to negotiate in good faith regarding the need for any treatment different from that otherwise provided herein to
ensure that (i) a federal income Tax deduction for the payment of such supplemental or deferred compensation or long-term incentive
award, annual incentive award or other compensation is not limited by reason of Section 162(m) of the Code, and (ii) the treatment
of such supplemental or deferred compensation or long-term incentive award, annual incentive award or other compensation does
not cause the imposition of a tax under Section 409A of the Code.

 

5.5
Access To Employees. On and after the Closing Date, BioTime and AgeX shall, or shall cause each of their respective Affiliates
to, make available to each other those of their employees who may reasonably be needed in order to defend or prosecute any Proceeding
which relates to a BioTime Benefit Plan or AgeX Benefit Plan and to which any employee or director of the BioTime Group or the
AgeX Group or any BioTime Benefit Plan or AgeX Benefit Plan is a party. The Party to whom an employee is made available in accordance
with this Section 5.5 shall pay or reimburse the other Party for all reasonable expenses which may be incurred by such employee
in connection therewith, including all reasonable travel, lodging, and meal expenses, but excluding any amount for such employee’s
time spent in connection with such Proceeding.

 

    	11

    	 

    

 

ARTICLE
6

MISCELLANEOUS

 

6.1
Complete Agreement; Construction. This Agreement, including any Exhibits and Schedules, and the ACA shall constitute the entire
agreement between the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments,
course of dealings and writings with respect to such subject matter. In the event of any inconsistency between this Agreement
and any Schedule hereto, the Schedule shall prevail. In the event and to the extent that there shall be a conflict between the
provisions of this Agreement and the provisions of the ACA, this Agreement shall control.

 

6.2
Counterparts. This Agreement may be executed in several counterparts, each of which shall constitute an original and all of
which, when taken together, shall constitute one agreement. The exchange of a fully executed Agreement (in counterparts or otherwise)
by electronic transmission or facsimile shall be sufficient to bind the Parties to the terms and conditions of this Agreement.

 

6.3
Waivers. No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver
of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall
preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No Party shall be deemed to
have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the
waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered
on behalf of such Party; and any such waiver shall not be applicable or have any effect except in the specific instance in which
it is given.

 

6.4
Assignment. This Agreement shall not be assignable, in whole or in part, directly or indirectly, by any Party without the
prior written consent of the other Party (not to be unreasonably withheld or delayed), and any attempt to assign any rights or
obligations arising under this Agreement without such consent shall be void. Notwithstanding the foregoing, this Agreement shall
be assignable to (i) an Affiliate or (ii) a bona fide third party in connection with a merger, reorganization, consolidation or
the sale of all or substantially all the assets of a Party so long as the resulting, surviving or transferee entity assumes all
the obligations of the assignor Party, by operation of law or pursuant to an agreement in form and substance reasonably satisfactory
to the other Party. No assignment permitted by this Section 6.4 shall release the assigning Party from liability for the full
performance of its obligations under this Agreement.

 

6.5
Successors and Assigns. The provisions of this Agreement and the obligations and rights hereunder shall be binding upon, inure
to the benefit of and be enforceable by (and against) the Parties and their respective successors and permitted transferees and
assigns.

 

6.6
Termination and Amendment.

 

(a)
This Agreement (including any Exhibits and Schedules) may be terminated, modified or amended at any time prior to the Distribution
Date by and in the sole discretion of BioTime without the approval of AgeX or the shareholders of BioTime. In the event of such
termination, no Party shall have any liability of any kind to the other Party or any other Person. After the Distribution Date,
this Agreement may not be terminated, modified or amended except by an agreement in writing signed by BioTime and AgeX.

 

    	12

    	 

    

 

(b)
Notwithstanding anything in this Agreement to the contrary, if the ACA is terminated before the Distribution Date, then all actions
and events that are under this Agreement to be taken or occur effective before, as of or following the Distribution Date, or otherwise
in connection with the Distribution, shall not be taken or occur except to the extent specifically agreed to in writing by the
Parties and neither Party shall have any Liability or further obligation to the other Party under this Agreement.

 

6.7
Subsidiaries. Each of the Parties shall cause to be performed, and hereby guarantees the performance of, all actions, agreements
and obligations set forth herein to be performed by any Subsidiary of such Party or by any entity that becomes a Subsidiary of
such Party at and after the Closing Date, to the extent such Subsidiary remains a Subsidiary of the applicable Party.

 

6.8
Third Party Beneficiaries. This Agreement is solely for the benefit of the Parties and should not be deemed to confer upon
third parties (including AgeX Group Employees) any remedy, claim, liability, reimbursement, claim of Action or other right in
excess of those existing without reference to this Agreement.

 

6.9
Title and Headings. The headings and titles of Articles, Sections and paragraphs contained in this Agreement are for convenience
of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction
or interpretation of this Agreement.

 

6.10
Exhibits and Schedules. The Exhibits and Schedules shall be construed with and as an integral part of this Agreement. Nothing
in the Exhibits or Schedules constitutes an admission of any liability or obligation of any BioTime Group Member or AgeX Group
Member, or any of their respective Affiliates, to any third party, nor, with respect to any third party, an admission against
the interests of any BioTime Group Member or the AgeX Group Member, or any of their respective Affiliates. The inclusion of any
item or Liability or category of item or Liability on any Exhibit or Schedule is made solely for purposes of allocating potential
Liabilities among the Parties and shall not be deemed as or construed to be an admission that any such Liability exists.

 

6.11
Governing Law. This Agreement and all claims or causes of action (whether in contract or tort or otherwise) based upon, arising
out of or related to this Agreement or the transactions contemplated hereby shall be governed by and construed in accordance with
the laws of the State of California without regard to conflict of laws principles that would result in the application of any
law other than the laws of the State of California, except to the extent the laws of the State of Delaware apply to the powers
and duties of the Board of Directors of AgeX or the other internal affairs of AgeX. Each of the parties hereto: (i) consents to
and submits to the exclusive jurisdiction and venue of the courts of the State of California or the United States District Court
for the Northern District of California, in any Proceeding arising out of or relating to this Agreement or any of the transactions
contemplated by this Agreement; (ii) agrees that all claims in respect of any such Proceeding shall be heard and determined in
any such court; (iii) shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from
any such court; and (iv) shall not bring any Proceeding arising out of or relating to this Agreement or any of the transactions
contemplated by this Agreement in any other court. Each of BioTime and AgeX hereby agrees that service of any process, summons,
notice or document in accordance with the provisions of this Agreement shall be effective service of process for any Proceeding
arising out of or relating to this Agreement or any of the transactions contemplated hereby.

 

    	13

    	 

    

 

6.12
Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability
of the offending term or provision in any other situation or in any other jurisdiction. If a court of competent jurisdiction declares
that any term or provision hereof is invalid or unenforceable, the Parties agree that the court making such determination shall
have the power to limit the term or provision, to delete specific words or phrases, and this Agreement shall be enforceable as
so modified. The Parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions
with valid provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable
provisions.

 

6.13
Interpretation. The Parties have participated jointly in the negotiation and drafting of this Agreement. This Agreement shall
be construed without regard to any presumption or rule requiring construction or interpretation against the Party drafting or
causing any instrument to be drafted.

 

6.14
No Duplication; No Double Recovery. Nothing in this Agreement is intended to confer to or impose upon any Party a duplicative
right, entitlement, obligation or recovery with respect to any matter arising out of the same facts and circumstances.

 

6.15
Notices. Any notice or other communication required or permitted to be delivered to any Party under this Agreement shall be
in writing and shall be deemed properly delivered, given and received: (a) at the time and date of delivery, when delivered by
hand; (b) the first Business Day if sent by next Business Day courier service; (c) at the time and date of delivery, if sent by
facsimile transmission before 5:00 p.m. in California, when the date and time of transmission is confirmed by the transmitting
equipment; (d) on the next Business Day, if sent by facsimile transmission after 5:00 p.m. in California, when the date and time
of transmission is confirmed by the transmitting equipment; in any case to the address or facsimile telephone number set forth
beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified
in a written notice given to the other parties hereto):

 

If
to AgeX:

1010
Atlantic Avenue

Suite
102

Alameda,
CA 94501

Attention:
Chief Executive Officer

Facsimile:
510-521-3389

 

If
to BioTime:

BioTime,
Inc.

1010
Atlantic Avenue

Suite
102

Alameda,
CA 94501

Attention:
Chief Financial Officer and General Counsel

Facsimile:
510-521-3389

 

[Signature
Page to the Employees Matters Agreement Follows]

 

    	14

    	 

    

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day and year first above written.

 

	 	BIOTIME,
    INC.
	 	 	 
	 	By:	/s/
    Aditya P. Mohanty
	 	 	Aditya
    P. Mohanty
	 	Title:	Co-Chief
Executive Officer
	 	 	 
	 	AGEX
    THERAPEUTICS, INC.
	 	 	 
	 	By:	/s/
    Michael D. West
	 	 	Michael
    D. West
	 	Title:
    	Chief
    Executive Officer

 

[Signature
Page to the Employees Matters Agreement]

 

    	15Execution
Version

 

TAX
MATTERS AGREEMENT

 

BY
AND AMONG

 

BIOTIME,
INC.

 

AND
ITS AFFILIATED COMPANIES

 

AND

 

AGEX
THERAPEUTICS, INC.

 

AND
ITS AFFILIATED COMPANIES

 

August
17, 2017

 

    	 

     

    

 

TABLE
OF CONTENTS

 

	ARTICLE
    I. DEFINITIONS	2
	Section
    1.01   Definitions	2
	 	 
	ARTICLE
    II. PREPARATION AND FILING OF TAX RETURNS PRIOR TO DECONSOLIDATION YEAR	7
	Section
    2.01   Manner of Filing.	7
	 	 
	ARTICLE
    III. ALLOCATION OF TAXES PRIOR TO DECONSOLIDATION YEAR	7
	Section
    3.01   Liability of the BioTime Group for Consolidated and Combined Taxes	7
	Section
    3.02   Liability of the AgeX Group for Consolidated and Combined Taxes	7
	Section
    3.03   BioTime Group Federal Income Tax Liability	7
	Section
    3.04   AgeX Group Federal Income Tax Liability	8
	Section
    3.05   BioTime Group Combined Tax Liability	9
	Section
    3.06   AgeX Group Combined Tax Liability	9
	Section
    3.07   Preparation and Delivery of Pro Forma Tax Returns	9
	Section
    3.08   Intercompany Payables and Receivables	9
	Section
    3.09   Credit for Use of Attributes	9
	Section
    3.10   Subsequent Changes in Treatment of Tax Items	10
	Section
    3.11   Foreign Corporations	10
	 	 
	ARTICLE
    IV. PREPARATION AND FILING OF TAX RETURNS FOR AND AFTER THE DECONSOLIDATION YEAR	11
	Section
    4.01   Manner of Filing.	11
	Section
    4.02   Pre-Deconsolidation Tax Returns	11
	Section
    4.03   Post-Deconsolidation Tax Returns.	11
	Section
    4.04   Accumulated Earnings and Profits, Initial Determination and Subsequent Adjustments	12
	Section
    4.05   Tax Basis of Assets Transferred	12
	 	 
	ARTICLE
    V. ALLOCATION OF TAXES FOR AND AFTER DECONSOLIDATION YEAR; ALLOCATION OF ADDITIONAL TAX LIABILITIES	12
	Section
    5.01   Liability of the BioTime Group for Consolidated and Combined Taxes	12
	Section
    5.02   Liability of the AgeX Group for Consolidated and Combined Taxes	12
	Section
    5.03   BioTime Group Federal Income Tax Liability	12
	Section
    5.04   AgeX Group Federal Income Tax Liability	13
	Section
    5.05   BioTime Group Combined Tax Liability	14
	Section
    5.06   AgeX Group Combined Tax Liability	14
	Section
    5.07   Preparation and Delivery of Pro Forma Tax Returns	14
	Section
    5.08   BioTime Intercompany Payables and Receivables; AgeX Payment	14
	Section
    5.09   Credit for Use of Attributes	14

 

    	 

     

    

 

	Section
    5.10   Subsequent Changes in Treatment of Tax Items	15
	Section
    5.11   Foreign Corporations	16
	Section
    5.12   Allocation of Additional Tax Liabilities.	16
	Section
    5.13   Tax Attributes of AgeX Not Carried Back	17
	 	 
	ARTICLE
    VI. TAX DISPUTE INDEMNITY; CONTROL OF PROCEEDINGS; COOPERATION AND EXCHANGE OF INFORMATION	18
	Section
    6.01   Tax Dispute Indemnity and Control of Proceedings.	18
	Section
    6.02   Cooperation and Exchange of Information.	19
	Section
    6.03   Reliance on Exchanged Information	20
	Section
    6.04   Payment of Tax and Indemnity	21
	 	 
	ARTICLE
    VII. WARRANTIES AND REPRESENTATIONS	21
	Section
    7.01   Warranties and Representations Relating to Actions of BioTime and AgeX	21
	Section
    7.02   Warranties and Representations Relating to the Distribution.	21
	Section
    7.03   Tax Records	22
	 	 
	ARTICLE
    VIII. MISCELLANEOUS PROVISIONS	22
	Section
    8.01   Notice	22
	Section
    8.02   Injunctions	23
	Section
    8.03   Further Assurances	24
	Section
    8.04   Parties in Interest	24
	Section
    8.05   Setoff	24
	Section
    8.06   Change of Law	24
	Section
    8.07   Termination and Survival	24
	Section
    8.08   Amendments; No Waivers.	24
	Section
    8.09   Governing Law and Interpretation	24
	Section
    8.10   Resolution of Certain Disputes	25
	Section
    8.11   Confidentiality	25
	Section
    8.12   Costs, Expenses and Attorneys’ Fees	25
	Section
    8.13   Counterparts	25
	Section
    8.14   Severability	26
	Section
    8.15   Entire Agreement; Termination of Prior Agreements.	26
	Section
    8.16   Assignment	26
	Section
    8.17   Fair Meaning	26
	Section
    8.18   Commencement	26
	Section
    8.19   Titles and Headings	26
	Section
    8.20   Construction	26
	Section
    8.21   Termination	26

 

    	 	ii 	 

     

    

 

TAX
MATTERS AGREEMENT

 

BY
AND BETWEEN

BIOTIME, INC. AND AGEX THERAPEUTICS, INC.

 

This
Tax Matters Agreement (the “Agreement”) is entered into as of August 17, 2017, by and between BioTime, Inc., a California
corporation (“BioTime”), and AgeX Therapeutics, Inc., a Delaware corporation (“AgeX”).

 

RECITALS

 

WHEREAS,
BioTime is the common parent of an affiliated group of corporations within the meaning of Section 1504(a) of the Code (as defined
herein), which currently files a consolidated federal income tax return;

 

WHEREAS,
BioTime and certain other entities and divisions comprise the “BioTime Group” which includes the entities described
in Exhibit A), and certain other entities and divisions comprise the “AgeX Group,” which includes the entities described
in Exhibit B);

 

WHEREAS,
the BioTime Group and the AgeX Group each include various corporations that join with BioTime in the filing of a consolidated
U.S. federal income tax return, as well as limited liability companies and other entities organized under the laws of domestic
and foreign jurisdictions;

 

WHEREAS,
BioTime recently contributed to AgeX certain assets and all of the stock it holds in each of the entities in the AgeX Group (other
than AgeX itself), solely in exchange for AgeX stock (the “Contribution”);

 

WHEREAS,
if determined by BioTime to be in the best interests of the shareholders of BioTime, BioTime may distribute all of its shares
of AgeX common stock, on a pro rata basis, to the holders of the common shares of BioTime, subject to the terms and conditions
of the Asset Contribution and Separation Agreement Asset Contribution Agreement (the “Distribution”);

 

WHEREAS,
it is anticipated that following the Distribution, AgeX may make an initial public offering (the “IPO”) of AgeX common
stock that may reduce its shareholders’ ownership of AgeX to not less than the amount required for such shareholders to
collectively control AgeX within the meaning of Section 368(c) of the Code with respect to the stock of AgeX and to not less than
the amount required for such shareholders to control AgeX within the meaning of Section 1504(a)(2) of the Code with respect to
the stock of AgeX;

 

WHEREAS,
immediately following the Deconsolidation (as defined below), BioTime and AgeX will cease to be members of the same affiliated
group for federal income tax purposes;

 

WHEREAS,
the Parties wish to set forth the general principles under which they will allocate and share various Taxes (as defined herein)
and related liabilities;

 

WHEREAS,
in contemplation of the IPO and the Deconsolidation, BioTime, on behalf of itself and its present and future subsidiaries other
than those included in the AgeX Group and AgeX, on behalf of itself and its present and future subsidiaries are entering into
this Agreement to provide for the allocation between the BioTime Group and the AgeX Group of all responsibilities, liabilities
and benefits relating to all Taxes paid or payable by either group for all taxable periods beginning on or after the Effective
Date (as defined herein) and to provide for certain other matters.

 

    	 

     

    

 

NOW,
THEREFORE, in consideration of the mutual agreements, provisions, and covenants contained in this Agreement, and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

 

ARTICLE
I.

 

DEFINITIONS

 

Section
1.01 Definitions.

 

The following terms shall have the following meanings (such meanings to be equally applicable to both
the singular and the plural forms of the terms defined):

 

“Accounting
Referee” is defined in Section 8.10 herein.

 

“Adequate
Assurances” means posting a bond or providing a letter of credit reasonably acceptable to the Indemnified Party; provided,
however, if the Indemnifying Party fails to post such bond or provide such letter of credit, the Indemnifying Party shall provide
cash equal to the Indemnity Amount to the Indemnified Party not less than thirty (30) days prior to the date on which such Tax
would become due and payable by the Indemnified Party.

 

“Affiliate”
of any person means any person, corporation, partnership or other entity directly or indirectly controlling, controlled by or
under common control with such person.

 

“Affiliated
Group” means an affiliated group of corporations within the meaning of Section 1504(a) (excluding Section 1504(b)) of
the Code for the taxable period in question.

 

“AgeX”
means AgeX from the Effective Date to the day immediately prior to the date of the IPO and means AgeX Therapeutics, Inc. from
and after the date of the IPO.

 

“AgeX
Affiliated Group” means, for each taxable period, the Affiliated Group of which AgeX or any successor of AgeX is the
common parent.

 

“AgeX
Allocated Attributes” has the meaning set forth in Section 3.09 or Section 5.09 of this Agreement as the case requires.

 

“AgeX
Businesses” means the present, former and future subsidiaries, divisions and businesses of any member of the AgeX Group
which are not, or are not contemplated by the Asset Contribution Agreement to be, part of the BioTime Group immediately after
the Deconsolidation Date.

 

“AgeX
Group” is defined in the Recitals to this Agreement.

 

    	 	2	 

     

    

 

“AgeX
Group Combined Tax Liability” means, with respect to any taxable period, the AgeX Group’s liability for Taxes
owed with respect to Combined Returns, as determined under Section 3.06 or Section 5.06 of this Agreement as the case requires.

 

“AgeX
Group Federal Income Tax Liability” means, with respect to any taxable period, the AgeX Group’s liability for
U.S. Federal Income Taxes, as determined under Section 3.04 or Section 5.04 of this Agreement as the case requires.

 

“AgeX
Group Members” means those entities or divisions of entities included in the AgeX Group as set forth on Exhibit B, hereto.

 

“AgeX
Group Pro Forma Combined Return” means a pro forma Combined Return or other schedule prepared pursuant to Section 3.06
or Section 5.06 of this Agreement as the case requires.

 

“AgeX
Group Pro Forma Consolidated Return” means a pro forma consolidated U.S. Federal Income Tax Return or other schedule
prepared pursuant to Section 3.04 or Section 5.04 of this Agreement as the case requires.

 

“AgeX
Restructuring Issue” is defined in Section 6.01(c) herein.

 

“AgeX
Stand-Alone Attributes” has the meaning set forth in Section 3.09(b) or Section 5.09(b) of this Agreement as the case
requires. “BioTime Affiliated Group” means, for each taxable period, the Affiliated Group of which BioTime
or any successor of BioTime is the common parent.

 

“Asset
Contribution Agreement” means that certain Asset Contribution Agreement entered into by BioTime and AgeX, dated August
17, 2017.

 

“BioTime
Affiliated Group Federal Income Tax Return” means the consolidated Federal income Tax Return of the BioTime Affiliated
Group.

 

“BioTime
Allocated Attributes” has the meaning set forth in Section 3.09 or Section 5.09 of this Agreement as the case requires.

 

“BioTime
Group” has the meaning set forth in the Recitals to this Agreement.

 

“BioTime
Group Combined Tax Liability” means, with respect to any taxable period, the BioTime Group’s liability for Taxes
owed with respect to Combined Returns, as determined under Section 3.05 or Section 5.05 of this Agreement as the case requires.

 

“BioTime
Group Federal Income Tax Liability” means, with respect to any taxable period, the BioTime Group’s liability for
Federal Income Taxes, as determined under Section 3.03 or Section 5.03 of this Agreement as the case requires.

 

“BioTime
Group Members” means those entities or divisions of entities included in the BioTime Group as set forth on Exhibit A,
hereto.

 

    	 	3	 

     

    

 

“BioTime
Group Pro Forma Combined Return” means a pro forma Combined Return or other schedule prepared pursuant to Section 3.05
or Section 5.05 of this Agreement as the case requires.

 

“BioTime
Group Pro Forma Consolidated Return” means a pro forma consolidated U.S. Federal Income Tax Return or other schedule
prepared pursuant to Section 3.03 or Section 5.03 of this Agreement as the case requires.

 

“BioTime
Stand-Alone Attributes” has the meaning set forth in Section 3.09(a) or Section 5.09(a) of this Agreement as the case
requires. “Code” means the Internal Revenue Code of 1986, as amended, or any successor thereto, as in effect
for the taxable period in question.

 

“Combined
Group” means a group of corporations or other entities that files a Combined Return.

 

“Combined
Return” means any Tax Return (other than for Federal Income Taxes) filed on a consolidated, combined (including nexus
combination, worldwide combination, domestic combination, line of business combination or any other form of combination), unitary
or group relief basis for members of the BioTime Group or the AgeX Group, or both, as the case may be.

 

“Consolidated
Group” means the affiliated group of corporations (as defined in Section 1504(a) of the Code) of which BioTime is the
common parent corporation.

 

“Consolidated
Return” means a Tax Return filed with respect to Federal Income Taxes for the Consolidated Group.

 

“Contribution”
is defined in the Recitals to this Agreement.

 

“Deconsolidation”
means the event that reduces the amount of AgeX stock owned directly or indirectly by BioTime to be less than the amount required
for BioTime to control AgeX within the meaning of Section 1504(a)(2) of the Code.

 

“Deconsolidation
Date” means the date the Deconsolidation occurs.

 

“Deconsolidation
Year” means the taxable year in which the Deconsolidation Date occurs.

 

“Disputed
Tax Issue” is defined in Section 6.01(a) herein.

 

“Disputed
Tax Issue Indemnitee” is defined in Section 6.01(a) herein.

 

“Disputed
Tax Issue Indemnitor” is defined in Section 6.01(a) herein.

 

“Distribution”
has the meaning set forth in the Recitals to this Agreement.

 

“Distribution
Date” is the date the Distribution occurs.

 

“Effective
Date” is August 17, 2017.

 

    	 	4	 

     

    

 

“Federal
Income Tax” means any Tax imposed under Subtitle A of the Code or any other provision of United States Federal Income
Tax law, and any interest, additions to Tax or penalties applicable or related thereto.

 

“Final
Determination” means the final resolution of any Tax (or other matter) for a taxable period, including related interest
or penalties, that, under applicable law, is not subject to further appeal, review or modification through proceedings or otherwise,
including (i) by the expiration of a statute of limitations or a period for the filing of claims for refunds, amending Tax Returns,
appealing from adverse determinations, or recovering any refund (including by offset), (ii) by a decision, judgment, decree, or
other order by a court of competent jurisdiction, which has become final and unappealable, (iii) by a closing agreement or an
accepted offer in compromise under Section 7121 or 7122 of the Code, or comparable agreements under laws of other jurisdictions,
(iv) by execution of an Internal Revenue Service Form 870 or 870-AD, or by a comparable form under the laws of other jurisdictions
(excluding, however, with respect to a particular Tax Item for a particular taxable period any such form that reserves (whether
by its terms or by operation of law) the right of the taxpayer to file a claim for refund and/or the right of the Tax Authority
to assert a further deficiency with respect to such Tax Item for such period), or (v) by any allowance of a refund or credit,
but only after the expiration of all periods during which such refund may be adjusted.

 

“Foreign
Tax Credit Adjustment” has the meaning set forth in Section 5.12(f) hereof.

 

“Group
Relief” has the meaning set forth in Section 5.12(c) hereof.

 

“IPO”
is defined in the Recitals to this Agreement.

 

“IRS”
means the United States Internal Revenue Service or any successor thereto, including, but not limited to, its agents, representatives,
and attorneys.

 

“Notice”
is defined in Section 8.01 herein.

 

“Party”
means each of BioTime and AgeX, and, solely for purposes of this definition, “BioTime” includes the BioTime Group
and “AgeX” includes the AgeX Group, all as of the Deconsolidation Date. Each of BioTime and AgeX shall cause the BioTime
Group and the AgeX Group, respectively, to comply with this Agreement.

 

“Post-Deconsolidation
Period” means any period beginning after the Deconsolidation Date.

 

“Pre-Deconsolidation
Period” means any period ending on or before the Deconsolidation Date.

 

“Required
Tax Attribute Carryback” is defined in Section 5.13 hereof.

 

“Restricted
Period” means the period beginning two years before the Distribution Date and ending two years after the Distribution
Date.

 

“Restructuring”
is defined in the Recitals to this Agreement.

 

    	 	5	 

     

    

 

“Restructuring
Taxes” means any and all Taxes resulting from the Restructuring and shall include any related interest, penalties, Tax
credit recapture or other additions to Tax, including, without limitation, any Tax imposed pursuant to, or as a result of, the
application of Section 311 of the Code.

 

“Spinoff”
means the separation of AgeX from BioTime through the Distribution.

 

“Tainting
Act” means (i) any act of omission or commission, including but not limited to, any transaction, representation, or
election which would constitute a breach by AgeX (or its successors) of the warranties, representations and covenants of Sections
7.02 or 7.03 hereof (without regard to whether a Subsequent Opinion had been obtained); or (ii) any transaction involving the
stock or assets of AgeX (or its successors) occurring after the Deconsolidation Date.

 

“Tax”
means any of the Taxes.

 

“Tax
Attribute” means one or more of the following attributes of a member of either the BioTime Group or the AgeX Group:
(i) with respect to the Consolidated Return, a net operating loss, a net capital loss, an unused investment credit, an unused
foreign tax credit, an excess charitable contribution, a U.S. federal minimum tax credit or U.S. federal general business credit
(but not tax basis or earnings and profits) and (ii) any comparable Tax Item reflected on a Combined Return.

 

“Tax
Authority” means a governmental authority (foreign or domestic) or any subdivision, agency, commission or authority
thereof or any quasi-governmental or private body having jurisdiction over the assessment, determination, collection or imposition
of any Tax (including, without limitation, the U.S. Internal Revenue Service).

 

“Tax
Controversy” means any audit, examination, dispute, suit, action, litigation or other judicial or administrative proceeding
initiated by AgeX, BioTime, the IRS or any other Tax Authority.

 

“Tax
Free Spinoff” is defined in Section 7.02(a) hereof.

 

“Tax
Item” means any item of income, gain, loss, deduction or credit, or other item reflected on a Tax Return or any Tax
Attribute.

 

“Tax
Return” means any return, report, certificate, form or similar statement or document (including, any related or supporting
information or schedule attached thereto and any information return, amended Tax Return, claim for refund or declaration of estimated
tax) required to be supplied to, or filed with, a Tax Authority in connection with the determination, assessment or collection
of any Tax or the administration of any laws, regulations or administrative requirements relating to any Tax.

 

“Taxes”
means all forms of taxation, whenever created or imposed, and whenever imposed by a national, local, municipal, governmental,
state, federation or other body, and without limiting the generality of the foregoing, shall include net income, alternative or
add-on minimum tax, gross income, sales, use, ad valorem, gross receipts, value added, franchise, profits, license, transfer,
recording, withholding, payroll, employment, excise, severance, stamp occupation, premium, property, windfall profit, custom duty,
or other tax, governmental fee or other like assessment or charge of any kind whatsoever, together with any related interest,
penalties, or other additions to tax, or additional amounts imposed by any such Tax Authority.

 

    	 	6	 

     

    

 

Any
term used but not capitalized herein that is defined in the Code or in the Treasury Regulations thereunder, shall to the extent
required by the context of the provision at issue, have the meaning assigned to it in the Code or such regulation.

 

ARTICLE
II.

PREPARATION AND FILING OF TAX RETURNS PRIOR TO DECONSOLIDATION YEAR

 

Section
2.01 Manner of Filing.

 

(a)
For periods prior to the Deconsolidation Year and except as provided in Section 2.0l(b) hereof, BioTime shall have the sole and
exclusive responsibility for the preparation and filing of, and shall prepare and file or cause to be prepared and filed: (1)
all Consolidated Returns and (2) all Combined Returns.

 

(b)
For periods prior to the Deconsolidation Year and except as otherwise provided in Section 2.0l(a) hereof, the BioTime Group and
the AgeX Group shall have the sole and exclusive responsibility for the preparation and filing of, and shall prepare and file
or cause to be prepared and filed, all Tax Returns of the BioTime Group Members and the AgeX Group Members that are not required
to be filed on a consolidated or combined basis. With respect to any Combined Return required to be filed in a foreign taxing
jurisdiction, BioTime shall determine, in its sole discretion, whether BioTime Group Members or AgeX Group Members, rather than
BioTime, shall have the responsibility for preparing and filing such Combined Return and the manner in which Taxes related to
such Combined Return shall be allocated and paid.

 

ARTICLE
III.

ALLOCATION OF TAXES PRIOR TO DECONSOLIDATION YEAR

 

Section
3.01 Liability of the BioTime Group for Consolidated and Combined Taxes. For each taxable year ending prior to the Deconsolidation
Year and beginning on or after the Effective Date, BioTime shall be liable for an amount equal to the BioTime Group Federal Income
Tax Liability and the BioTime Group Combined Tax Liability.

 

Section
3.02 Liability of the AgeX Group for Consolidated and Combined Taxes. For each taxable year
ending prior to the Deconsolidation Year and beginning on or after the Effective Date, the AgeX Group shall be liable to BioTime
for an amount equal to the AgeX Group Federal Income Tax Liability and the AgeX Group Combined Tax Liability.

 

Section
3.03 BioTime Group Federal Income Tax Liability. With respect to each taxable year ending
prior to the Deconsolidation Year and beginning on or after the Effective Date, the BioTime Group Federal Income Tax Liability
for such taxable period shall be the Federal Income Taxes for such taxable period, as determined on a BioTime Group Pro Forma
Consolidated Return prepared:

 

    	 	7	 

     

    

 

(a)
assuming that the members of the BioTime Group were not included in the Consolidated Group and by including only Tax Items of
members of the BioTime Group that are included in the Consolidated Return;

 

(b)
except as provided in Section 3.03(e) hereof, using all elections, accounting methods and conventions used on the Consolidated
Return for such period;

 

(c)
applying the highest statutory marginal corporate income Tax rate in effect for such taxable period;

 

(d)
excluding any Tax Attributes for which BioTime has been compensated pursuant to Section 3.09 hereof;

 

(e)
assuming that the BioTime Group elects not to carry back any net operating losses; and

 

(f)
assuming that the BioTime Group’s utilization of any Tax Attribute carryforward or carryback is limited to the Tax Attributes
of the BioTime Group that would be available if the BioTime Group Federal Income Tax Liability for each taxable year ending after
January 1, 2011 were determined in accordance with this Section 3.03.

 

Section
3.04 AgeX Group Federal Income Tax Liability. With respect to each taxable year ending prior to the Deconsolidation Year
and beginning on or after the Effective Date, the AgeX Group Federal Income Tax Liability for such taxable period shall be the
Federal Income Taxes for such taxable period, as determined on an AgeX Group Pro Forma Consolidated Tax Return prepared:

 

(a)
assuming that the members of the AgeX Group were not included in the Consolidated Group and by including only Tax Items of members
of the AgeX Group that are included in the Consolidated Return;

 

(b)
except as provided in Section 3.04(e) hereof, using all elections, accounting methods and conventions used on the Consolidated
Return for such period;

 

(c)
applying the highest statutory marginal corporate income Tax rate in effect for such taxable period;

 

(d)
excluding any Tax Attributes for which AgeX has been compensated pursuant to Section 3.09 hereof;

 

(e)
assuming that the AgeX Group elects not to carry back any net operating losses; and

 

(f)
assuming that the AgeX Group’s utilization of any Tax Attribute carryforward or carryback is limited to the Tax Attributes
of the AgeX Group that would be available if the AgeX Group Federal Income Tax Liability for each taxable year ending after January
1, 2011 were determined in accordance with this Section 3.04.

 

    	 	8	 

     

    

 

Section
3.05 BioTime Group Combined Tax Liability. With respect to any taxable year ending prior to the Deconsolidation Year and
beginning on or after the Effective Date, the BioTime Group Combined Tax Liability shall be the sum for such taxable period of
the BioTime Group’s liability for Taxes owed with respect to Combined Returns, as determined on the BioTime Group Pro Forma
Combined Returns prepared in a manner consistent with the principles and procedures set forth in Section 3.03 hereof.

 

Section
3.06 AgeX Group Combined Tax Liability. With respect to any taxable year ending prior to the Deconsolidation Year and beginning
on or after the Effective Date, the AgeX Group Combined Tax Liability shall be the sum for such taxable period of the AgeX Group’s
liability for Taxes owed with respect to Combined Returns, as determined on the AgeX Group Pro Forma Combined Returns prepared
in a manner consistent with the principles and procedures set forth in Section 3.04 hereof.

 

Section
3.07 Preparation and Delivery of Pro Forma Tax Returns. Not later than ninety (90) days following the date on which the
related Consolidated Return or Combined Return, as the case may be, is filed with the appropriate Tax Authority, BioTime shall
prepare and deliver to AgeX pro forma Tax Returns calculating (i) the BioTime Group Federal Income Tax Liability or the BioTime
Group Combined Tax Liability, and (ii) the AgeX Group Federal Income Tax Liability or the AgeX Group Combined Tax Liability, which
is attributable to the period covered by such filed Tax Return.

 

Section
3.08 Intercompany Payables and Receivables. The liability of the BioTime Group and the AgeX
Group for (i) the BioTime Group Federal Income Tax Liability and BioTime Group Combined Tax Liability, and (ii) the AgeX Group
Federal Income Tax Liability and AgeX Group Combined Tax Liability, respectively, shall be reflected in the intercompany accounts
of BioTime or AgeX, as the case may be, to the extent such liabilities are paid by BioTime or other person who is not a member
of the AgeX Group.

 

Section
3.09 Credit for Use of Attributes. Not later than ninety (90) days following the filing of
the Consolidated Return for each taxable year, BioTime shall determine the aggregate amount of the Tax Attributes of the Consolidated
Group and all Combined Groups that are allocable to the BioTime Group (the “BioTime Allocated Attributes”) and the
AgeX Group (the “AgeX Allocated Attributes”) as of the end of such year and shall inform AgeX of such determination.

 

(a)
If the amount of the BioTime Allocated Attributes is less than the amount of Tax Attributes (as reasonably determined by BioTime)
that would have been available to the BioTime Group at the end of such year had the BioTime Group Members not been included in
the Consolidated Return and the Combined Returns (the “BioTime Stand-Alone Attributes”), the value of such shortfall,
to the extent such shortfall is attributable to the use of the BioTime Group’s Tax Attributes by AgeX Group Members, shall
be reflected in the intercompany accounts as an amount payable by AgeX to BioTime. If the amount of the BioTime Allocated Attributes
is greater than the BioTime Stand-Alone Attributes, the value of such excess, to the extent such excess is attributable to the
use of Tax Attributes of AgeX Group Members by BioTime Group Members during such year, shall be reflected in the intercompany
accounts as an amount payable by BioTime to AgeX. For this purpose, a Tax Attribute shall be treated as used by AgeX Group Members
or BioTime Group Members only to the extent that such Tax Attribute is necessary to reduce the AgeX Group Federal Income Tax Liability
or BioTime Group Federal Income Tax Liability (computed in accordance with Section 3.04 or 3.03) for such year. In calculating
the BioTime Stand-Alone Attributes, the utilization of any Tax Attribute carryforward by BioTime Group Members shall be subject
to the limitation described in Section 3.03(f) hereof. For purposes of this section, the value of any Tax Attribute shall be equal
to the amount of Taxes (computed in accordance with Section 3.03 hereof) that would be avoided by the payor if it had sufficient
income to fully utilize such Tax Attribute in such year.

 

    	 	9	 

     

    

 

(b)
If the amount of the AgeX Allocated Attributes is less than the amount of Tax Attributes (as reasonably determined by BioTime)
that would have been available to the AgeX Group at the end of such year had the AgeX Group Members not been included in the Consolidated
Return and the Combined Returns (the “AgeX Stand-Alone Attributes”), the value of such shortfall, to the extent such
shortfall is attributable to the use of the AgeX Group’s Tax Attributes by BioTime Group Members, shall be reflected in
the intercompany accounts as an amount payable by BioTime to AgeX. If the amount of the AgeX Allocated Attributes is greater than
the AgeX Stand-Alone Attributes, the value of such excess, to the extent such excess is attributable to the use of Tax Attributes
of BioTime Group Members by AgeX Group Members during such year, shall be reflected in the intercompany accounts as an amount
payable by AgeX to BioTime. For this purpose, a Tax Attribute shall be treated as used by BioTime Group Members or AgeX Group
Members only to the extent that such Tax Attribute is necessary to reduce the BioTime Group Federal Income Tax Liability or AgeX
Group Federal Income Tax Liability (computed in accordance with Section 3.03 or 3.04) for such year. In calculating the AgeX Stand-Alone
Attributes, the utilization of any Tax Attribute carryforward by AgeX Group Members shall be subject to the limitation described
in Section 3.04(f) hereof. For purposes of this section, the value of any Tax Attribute shall be equal to the amount of Taxes
(computed in accordance with Section 3.04 hereof) that would be avoided by the payor if it had sufficient income to fully utilize
such Tax Attribute in such year.

 

Section
3.10 Subsequent Changes in Treatment of Tax Items. For any taxable year ending prior to the Deconsolidation Year and beginning
on or after the Effective Date, in the event of a change in the treatment of any Tax Item of any member of the Consolidated Group
or a Combined Group as a result of a Final Determination, BioTime shall calculate (i) the change to the BioTime Group Federal
Income Tax Liability or BioTime Group Combined Tax Liability and/or the AgeX Group Federal Income Tax Liability or the AgeX Group
Combined Tax Liability and (ii) any change to the Allocated Attributes and/or the Stand-Alone Attributes of the BioTime Group
and the AgeX Group, and such changes shall be properly reflected in the intercompany accounts described in Section 3.09 hereof.

 

Section
3.11 Foreign Corporations. Any Taxes associated with the filing of a separate Tax Return in a foreign jurisdiction with
respect to an BioTime Group Member or a AgeX Group Member shall be allocated to and paid directly by such member. Any Taxes and
Tax Attributes associated with the filing of a separate Tax Return in a foreign jurisdiction that includes the Tax Items of one
or more BioTime Group Members and one or more AgeX Group Members shall be allocated to such members by BioTime in a manner consistent
with the principles set forth in this Article III.

 

    	 	10	 

     

    

 

ARTICLE
IV.

 

PREPARATION
AND FILING OF TAX RETURNS FOR AND AFTER THE DECONSOLIDATION YEAR

 

Section
4.01 Manner of Filing.

 

(a)
Except to the extent otherwise provided herein, all Tax Returns filed with federal and state Tax Authorities of the United States
for the Deconsolidation Year and for two taxable years following the Deconsolidation Year by BioTime or by AgeX shall be prepared
(in the absence of a controlling change in law or circumstances or consent of BioTime with such consent not to be unreasonably
withheld) consistent with past practices, elections, accounting methods, conventions, and principles of taxation used for the
most recent taxable periods for which Tax Returns involving similar items have been filed prior to the Deconsolidation Date.

 

(b)
For a period of two fiscal years following the Distribution Date, all Tax Returns filed by BioTime and AgeX after the Distribution
Date shall be prepared on a basis that is consistent with Pre-Deconsolidation Period practice of BioTime and AgeX (in the absence
of a controlling change in law or circumstances), and shall be filed on a timely basis by the Party responsible for such filing
under this Agreement.

 

Section
4.02 Pre-Deconsolidation Tax Returns. Except as provided in Section 4.03(b) hereof, all Tax
Returns required to be filed for the portion of the Deconsolidation Year ending on the Deconsolidation Date shall be filed by
the party who would bear responsibility under Section 2.01 hereof if such Tax Returns were for periods prior to the Deconsolidation
Year.

 

Section
4.03 Post-Deconsolidation Tax Returns.

 

(a)
All Tax Returns of the AgeX Group for the portion of the Deconsolidation Year beginning after the Deconsolidation Date and all
periods after the Deconsolidation Year shall be filed by AgeX and all Tax Returns of the BioTime Group for the portion of the
Deconsolidation Year beginning after the Deconsolidation Date and all periods after the Deconsolidation Year shall be filed by
BioTime.

 

(b)
All AgeX Group foreign, state or local income Tax Returns for the Deconsolidation Year that are filed based on a complete fiscal
year (i.e. there is not a Tax year end as of the Deconsolidation Date) shall be filed by AgeX.

 

(c)
If Deconsolidation occurs for federal Tax purposes but not for Combined Return purposes, i.e., there is more than 50% but
less than 80% ownership of AgeX stock by BioTime, the BioTime and AgeX Tax departments will develop procedures consistent with
this Agreement for handling such Combined Returns.

 

    	 	11	 

     

    

 

Section
4.04 Accumulated Earnings and Profits, Initial Determination and Subsequent Adjustments. Within ninety (90) days following
the Distribution Date, BioTime shall notify AgeX of the balance of accumulated earnings and profits on BioTime’s Tax records
as of the Distribution Date which are allocable to the AgeX Businesses, as calculated in accordance with the appropriate provisions
of the Code and the Treasury Regulations thereunder (including Section 312(h) of the Code and Treasury Regulations § 1.312-10
or any successor regulation thereto) by BioTime. The notice provided by BioTime to AgeX hereunder shall include supporting documentation
which details the calculation of earnings and profits allocated to the AgeX Businesses as of the Distribution Date. Within sixty
(60) days after filing the BioTime Affiliated Group Federal Income Tax Return for the taxable year that includes the Distribution
Date, BioTime shall notify AgeX of any adjustments in the BioTime earnings and profits as of the Distribution Date and shall provide
to AgeX supporting documentation which details the recalculation of BioTime earnings and profits allocable to the AgeX Businesses
as of the Distribution Date. If in subsequent Tax years, a Final Determination results in an adjustment to the accumulated earnings
and profits on the Tax records of BioTime as of the Distribution Date, BioTime shall promptly notify AgeX of the adjustment within
sixty (60) days after receiving written notice of such Final Determination, and shall provide AgeX with supporting documentation
which details the recalculation of BioTime earnings and profits allocable to the AgeX Businesses as of the Distribution Date.

 

Section
4.05 Tax Basis of Assets Transferred. Within ninety (90) days following the Distribution
Date, BioTime shall notify AgeX of the Tax basis of the stock of any corporation or other assets transferred to AgeX in the Restructuring.1
In the event that a Final Determination results in an adjustment to the basis of such stock, BioTime shall notify AgeX within
sixty (60) days of receiving written notice of such Final Determination, of the nature and amount of the adjustments and shall
provide AgeX with supporting documentation detailing the calculation of such adjustments.

 

ARTICLE
V.

ALLOCATION OF TAXES FOR AND AFTER DECONSOLIDATION YEAR; ALLOCATION OF ADDITIONAL TAX LIABILITIES

 

Section
5.01 2Liability of the BioTime Group for Consolidated and Combined Taxes. For
the Deconsolidation Year and all taxable years following the Deconsolidation Year, BioTime shall be liable for an amount equal
to the BioTime Group Federal Income Tax Liability and the BioTime Group Combined Tax Liability.

 

Section
5.02 Liability of the AgeX Group for Consolidated and Combined Taxes. For the Deconsolidation Year, the AgeX Group shall
be liable to BioTime for an amount equal to the AgeX Group Federal Income Tax Liability and the AgeX Group Combined Tax Liability.

 

Section
5.03 BioTime Group Federal Income Tax Liability. With respect to the Deconsolidation Year and all taxable years following
the Deconsolidation Year, the BioTime Group Federal Income Tax Liability for such taxable period shall be the Federal Income Taxes
for such taxable period, as determined on an BioTime Group Pro Forma Consolidated Return prepared:

  

    	 	12	 

     

    

 

(a)
assuming that the members of the BioTime Group were not included in the Consolidated Group and by including only Tax Items of
members of the BioTime Group that are included in the Consolidated Return;

 

(b)
except as provided in Section 5.03(e) hereof, using all elections, accounting methods and conventions used on the Consolidated
Return for such period;

 

(c)
applying the highest statutory marginal corporate income Tax rate in effect for such taxable period;

 

(d)
excluding any Tax Attributes for which BioTime has been compensated pursuant to Section 5.09 hereof;

 

(e)
assuming that the BioTime Group elects not to carry back any net operating losses; and

 

(f)
assuming that the BioTime Group’s utilization of any Tax Attribute carryforward or carryback is limited to the Tax Attributes
of the BioTime Group that would be available if the BioTime Group Federal Income Tax Liability for each taxable year ending after
January 1, 2011 were determined in accordance with this Section 5.03.

 

Section
5.04 AgeX Group Federal Income Tax Liability. With respect to the Deconsolidation Year, the AgeX Group Federal Income
Tax Liability for such taxable period shall be the Federal Income Taxes for such taxable period, as determined on an AgeX Group
Pro Forma Consolidated Tax Return prepared:

 

(a)
assuming that the members of the AgeX Group were not included in the Consolidated Group and by including only Tax Items of members
of the AgeX Group that are included in the Consolidated Return;

 

(b)
except as provided in Section 5.04(e) hereof, using all elections, accounting methods and conventions used on the Consolidated
Return for such period;

 

(c)
applying the highest statutory marginal corporate income Tax rate in effect for such taxable period;

 

(d)
excluding any Tax Attributes for which AgeX has been compensated pursuant to Section 5.09 hereof;

 

(e)
assuming that the AgeX Group elects not to carry back any net operating losses; and

 

(f)
assuming that the AgeX Group’s utilization of any Tax Attribute carryforward or carryback is limited to the Tax Attributes
of the AgeX Group that would be available if the AgeX Group Federal Income Tax Liability for each taxable year ending after January
1, 2011 were determined in accordance with this Section 5.04.

 

    	 	13	 

     

    

 

Section
5.05 BioTime Group Combined Tax Liability. With respect to the Deconsolidation Year and all
taxable years following the Deconsolidation Year, the BioTime Group Combined Tax Liability shall be the sum for such taxable period
of the BioTime Group’s liability for Taxes owed with respect to Combined Returns, as determined on the BioTime Group Pro
Forma Combined Returns prepared in a manner consistent with the principles and procedures set forth in Section 5.03 hereof, without
recalculating the state apportionment factors.

 

Section
5.06 AgeX Group Combined Tax Liability. With respect to the Deconsolidation Year, the AgeX Group Combined Tax Liability
shall be the sum for such taxable period of the AgeX Group’s liability for Taxes owed with respect to Combined Returns,
as determined on the AgeX Group Pro Forma Combined Returns prepared in a manner consistent with the principles and procedures
set forth in Section 5.04 hereof, without recalculating the state apportionment factors and assuming that Tax Items of the AgeX
Group are not included in the Combined Returns of the BioTime Group following the Deconsolidation Date.

 

Section
5.07 Preparation and Delivery of Pro Forma Tax Returns. Not later than ninety (90) days following the date on which the
related Consolidated Return or Combined Return, as the case may be, is filed with the appropriate Tax Authority, BioTime shall
prepare and deliver to AgeX pro forma Tax Returns calculating (i) the BioTime Group Federal Income Tax Liability or the BioTime
Group Combined Tax Liability, and (ii) the AgeX Group Federal Income Tax Liability or the AgeX Group Combined Tax Liability, which
is attributable to the period covered by such filed Tax Return.

 

Section
5.08 BioTime Intercompany Payables and Receivables; AgeX Payment. The liability of the BioTime
Group for the BioTime Group Federal Income Tax Liability and BioTime Group Combined Tax Liability shall be reflected in the intercompany
accounts of BioTime. For the Deconsolidation Year, AgeX will pay BioTime for the AgeX Group Federal Income Tax Liability and the
AgeX Group Combined Tax Liability within sixty (60) days following the delivery to AgeX by BioTime of a AgeX Group Pro Forma Consolidated
Tax Return or a AgeX Group Pro Forma Combined Return, as the case may be, to the extent such Tax liabilities are paid by BioTime
or other person who is not a member of the AgeX Group. For the Deconsolidation Year, any payment due from AgeX described in the
previous sentence shall be decreased by the cumulative amount of payments made by AgeX to BioTime to fund BioTime’s estimated
Tax payments with respect to Taxes for the Deconsolidation Year.

 

Section
5.09 Credit for Use of Attributes. Not later than sixty (60) days following the filing of
the Consolidated Return for the Deconsolidation Year, BioTime shall determine the aggregate amount of the Tax Attributes of the
Consolidated Group and all Combined Groups that are allocable to the AgeX Group (the “AgeX Allocated Attributes”)
as of the end of such year and shall inform AgeX of such determination.

 

(a)
If the amount of the BioTime Allocated Attributes is less than the amount of Tax Attributes (as reasonably determined by BioTime)
that would have been available to the BioTime Group at the end of such year had the BioTime Group Members not been included in
the Consolidated Return and the Combined Returns (the “BioTime Stand-Alone Attributes”), the value of such shortfall,
to the extent such shortfall is attributable to the use of the BioTime Group’s Tax Attributes by AgeX Group Members, shall
be reflected in the intercompany accounts as an amount payable by AgeX to BioTime. If the amount of the BioTime Allocated Attributes
is greater than the BioTime Stand-Alone Attributes, the value of such excess, to the extent such excess is attributable to the
use of Tax Attributes of AgeX Group Members by BioTime Group Members during such year, shall be reflected in the intercompany
accounts as an amount payable by BioTime to AgeX. For this purpose, a Tax Attribute shall be treated as used by AgeX Group Members
or BioTime Group Members only to the extent that such Tax Attribute is necessary to reduce the AgeX Group Federal Income Tax Liability
or BioTime Group Federal Income Tax Liability (computed in accordance with Section 5.04 or 5.03) for such year. In calculating
the Stand-Alone Attributes, the utilization of any Tax Attribute carryforward by BioTime Group Members shall be subject to the
limitation described in Section 5.03(f) hereof. For purposes of this section, the value of any Tax Attribute shall be equal to
the amount of Taxes (computed in accordance with Section 5.03 hereof) that would be avoided by the payor if it had sufficient
income to fully utilize such Tax Attribute in such year.

 

    	 	14	 

     

    

 

(b)
If the amount of the AgeX Allocated Attributes for the Pre-Deconsolidation Period is less than the amount of Tax Attributes (as
reasonably determined by BioTime) that would have been available to the AgeX Group for the Pre-Deconsolidation Period had the
AgeX Group Members not been included in the Consolidated Return and the Combined Returns (the “AgeX Stand-Alone Attributes”),
the value of such shortfall, to the extent such shortfall is attributable to the use of the AgeX Group’s Tax Attributes
by BioTime Group Members, shall be paid by BioTime to AgeX within thirty (30) days of the date the AgeX Allocated Attributes are
determined. If the amount of the AgeX Allocated Attributes for the Pre-Deconsolidation Period is greater than the amount of the
AgeX Stand-Alone Attributes, the value of such excess shall be paid by AgeX to BioTime within thirty (30) days of the date the
AgeX Allocated Attributes are determined. For this purpose, a Tax Attribute shall be treated as used by BioTime Group Members
or AgeX Group Members only to the extent that such Tax Attribute is necessary to reduce the BioTime Group Federal Income Tax Liability
or AgeX Group Federal Income Tax Liability (computed in accordance with Section 5.03 or 5.04) for such year. In calculating the
AgeX Stand-Alone Attributes, the utilization of any Tax Attribute carryforward by AgeX Group Members shall be subject to the limitation
described in Section 5.04(f) hereof. For purposes of this section, the value of any Tax Attribute shall be equal to the amount
of Taxes (computed in accordance with Section 5.04 hereof) that would be avoided by the payor if it had sufficient income to fully
utilize such Tax Attribute in such year.

 

Section
5.10 Subsequent Changes in Treatment of Tax Items. For the Deconsolidation Year and all taxable
years following the Deconsolidation Year, in the event of a change in the treatment of any Tax Item of any member of the Consolidated
Group or a Combined Group as a result of a Final Determination, BioTime shall calculate (i) the change to the BioTime Group Federal
Income Tax Liability or BioTime Group Combined Tax Liability and (ii) any change to the Allocated Attributes and/or the Stand-Alone
Attributes of the BioTime Group, and such changes shall be properly reflected in the intercompany accounts described in Section
5.09(a) hereof. For the Deconsolidation Year, in the event of a change in the treatment of any Tax Item of any member of the Consolidated
Group or a Combined Group as a result of a Final Determination, BioTime shall calculate (i) the change to the AgeX Group Federal
Income Tax Liability or AgeX Group Combined Tax Liability and (ii) any change to the Allocated Attributes and/or the Stand-Alone
Attributes of the AgeX Group and such changes shall be properly reflected in payments from BioTime to AgeX, or from AgeX to BioTime,
as the case may be.

 

    	 	15	 

     

    

 

Section
5.11 Foreign Corporations. Any Taxes associated with the filing of a separate Tax Return
in a foreign jurisdiction with respect to an BioTime Group Member or a AgeX Group Member shall be allocated to and paid directly
by such member. For the Deconsolidation Year any Taxes and Tax Attributes associated with the filing of a separate Tax Return
in a foreign jurisdiction that includes the Tax Items of one or more BioTime Group Members and one or more AgeX Group Members
shall be allocated to such members by BioTime in a manner consistent with the principles set forth in this Article V.

 

Section
5.12 Allocation of Additional Tax Liabilities.

 

(a)
Restructuring Taxes. Notwithstanding that the Restructuring occurred prior to the Effective Date, notwithstanding any other
provision of this Agreement to the contrary, and except as otherwise provided in the Asset Contribution Agreement and Section
5.12(a)(i) hereof, BioTime shall pay and shall indemnify and hold harmless AgeX and any member of the AgeX Group from and against
any and all Restructuring Taxes, without regard to any benefit that any member of the AgeX Group might derive as a result of the
payment of the Restructuring Taxes by BioTime. BioTime shall also be liable for all fees, costs and expenses, including reasonable
attorneys’ fees, arising out of, or incident to, any proceedings before any Tax Authority, or any judicial authority, with
respect to any amount for which it is liable for under Section 5.12(a) hereof.

 

(i)
In the event any Restructuring Taxes are attributable to a Tainting Act of AgeX or any member of the AgeX Group, then AgeX shall
pay and shall indemnify and hold harmless BioTime from and against any and all Restructuring Taxes and from and against any costs
whatsoever connected with such Taxes, including, but not limited to, fees, interest, penalties, and expenses, including reasonable
attorneys’ fees. For purposes of this Section 5.12(a)(i), a Restructuring Tax is attributable to a Tainting Act if (1) such
Tax would not have been imposed but for the Tainting Act, or (2) the Tainting Act would have independently caused the imposition
of such Tax; provided, however, that in no event shall a Restructuring Tax be considered attributable to a Tainting Act to the
extent such Tax would not have been incurred but for a breach by BioTime of any warranty, representation or covenant contained
in Article VII hereof.

 

(ii)
An indemnification payment required to be made by one Party pursuant to Section 5.12(a) hereof shall be paid in immediately available
funds within thirty (30) days after receiving a written demand from the other Party for such payment; however, no Party shall
make a written demand for an indemnification payment attributable to Restructuring Taxes under Section 5.12(a) hereof until such
Tax liability is established by a Final Determination. Any indemnification payment required to be made by either Party under Section
5.12(a) hereof which is not paid timely shall bear interest (compounded daily) at the Federal short-term rate or rates established
pursuant to Section 6621 of the Code for the period during which such payment is due but unpaid.

 

(b)
Dual Consolidated Losses. Notwithstanding any other provisions of this Agreement, whether before or during the Deconsolidation
Year, to the extent a member of the AgeX Group is responsible for a triggering event (as defined in Treasury Regulations §
1.1503-2(g)(2)(iii)(A)) that causes BioTime to recapture and report as income for any Tax period the amount of a dual consolidated
loss (as defined in Treasury Regulations § 1.1503-2), AgeX shall pay to BioTime on a timely basis any Tax attributable to
the recapture of such dual consolidated loss. AgeX hereby assumes all liability for any such Tax and shall indemnify and hold
harmless BioTime and any member of the BioTime Group for such liability; provided, however, to the extent any such recapture is
attributable to a triggering event resulting from the Spinoff, AgeX shall not be liable for any Tax resulting from such recapture.

 

    	 	16	 

     

    

 

(c)
Refunds. Each Party shall be entitled to retain or be paid all refunds of Tax received, whether in the form of payment,
credit or otherwise, from any Tax Authority with respect to any Tax for which such Party is responsible under this Article V.

 

(d)
Allocation of Taxable Items. BioTime shall determine the amounts of income, gain, loss, deduction, and credit of the AgeX
Group for the Pre-Deconsolidation Period that are properly includible in the Consolidated Return for the taxable year which includes
the Deconsolidation Date. For all relevant purposes of this Agreement, the members of the AgeX Group and each AgeX Combined Group
shall cease to be members of the Consolidated Group as of the end of the Deconsolidation Date, and the AgeX Group shall cause
the book of account of the AgeX Group to be closed for accounting and Tax purposes as of the end of the Deconsolidation Date in
accordance with BioTime’s direction. In determining consolidated taxable income for the taxable period that ends on the
Deconsolidation Date, the income and other items of the AgeX Group shall be determined in good faith by BioTime in accordance
with Treasury Regulations §§ 1.1502-76(b)(1), 1.1502-76(b)(2)(i) and 1.1502-76(b)(2)(iv) and no election shall be made
under § 1.1502-76(b)(2)(ii)(D) to ratably allocate items. However, an allocation shall be made in good faith by BioTime under
Treasury Regulations § 1.1502-76(b)(2)(iii) if such allocation is determined by BioTime in good faith to be necessary to
appropriately allocate items in the event the Deconsolidation Date occurs on any date other than the last day of any month.

 

(e)
Foreign Tax Credit True-Up. With respect to the Deconsolidation Year, no later than ninety (90) days following the filing
of a Consolidated Return, an amended Consolidated Return or a final settlement with the U.S. Internal Revenue Service, BioTime
shall determine the aggregate amount of the “Foreign Tax Credit Adjustment.” The Foreign Tax Credit Adjustment shall
be equal to (x) the aggregate amount of foreign Taxes paid by members of the AgeX Group and allowable as foreign tax credits for
United States federal income tax purposes for the period commencing January 1, 2011, and ending on the Deconsolidation Date, minus
(y) the sum of (i) the amount of reduction of the AgeX Group’s Federal Income Tax Liability pursuant to Section 3.04 and
Section 5.04 hereof resulting from foreign tax deductions and credits; plus (ii) the amount of credit that the AgeX Group received
with respect to foreign Taxes pursuant to Section 3.09 and Section 5.09 hereof; plus (iii) the amount of the foreign Taxes for
the period commencing January 1, 2011, allocated to the AgeX Group upon Deconsolidation pursuant to Treasury Regulations §
1.1502-79(d). If the Foreign Tax Credit Adjustment pursuant to the preceding sentence is a positive amount, BioTime shall pay
such amount to the AgeX Group. If the amount determined pursuant to the preceding sentence is a negative amount, the AgeX Group
shall pay such amount to BioTime.

 

Section
5.13 Tax Attributes of AgeX Not Carried Back. With respect to any Tax Attributes incurred by the AgeX Group in a Post-Deconsolidation
Period, AgeX shall not, and shall cause each member of the AgeX Group to not, elect to carry back Tax Attributes to a Pre-Deconsolidation
Period. In the event the applicable Tax law requires a Tax Attribute of the AgeX Group arising in a Post-Deconsolidation Period
to be carried back to a Pre-Deconsolidation Period Tax Return of BioTime or other member of the BioTime Group (such Tax Attribute
being a “Required Tax Attribute Carryback”), AgeX shall notify BioTime of such Required Tax Attribute Carryback sixty
(60) days prior to the date such Tax Return must be filed and AgeX shall timely provide BioTime with all information reasonably
necessary to properly account for such Required Tax Attribute Carryback on such Tax Return. If a Required Tax Attribute Carryback
that is reported on a Tax Return filed by BioTime or other member of the BioTime Group produces an actual Tax savings to BioTime
or other member of the BioTime Group, BioTime shall pay AgeX an amount equal to such savings within sixty (60) days following
the filing of such Tax Return.

 

    	 	17	 

     

    

 

ARTICLE
VI.

TAX DISPUTE INDEMNITY; CONTROL OF PROCEEDINGS; COOPERATION AND EXCHANGE OF INFORMATION

 

Section
6.01 Tax Dispute Indemnity and Control of Proceedings.

 

(a)
Whenever a Party becomes aware of the existence of an issue which relates to any Tax liability of the other Party (a “Disputed
Tax Issue” of such other Party), and the rights or responsibilities under this Agreement of such Party may be affected by
the resolution of such Disputed Tax Issue, such Party (a “Disputed Tax Issue Indemnitee”) shall promptly notify the
other Party (the “Disputed Tax Issue Indemnitor”) of the Disputed Tax Issue. The Disputed Tax Issue Indemnitor has
the right to defend, handle, settle or contest at its cost any Disputed Tax Issue.

 

(b)
Except as provided in this Article VI, BioTime shall have full responsibility and discretion in handling, settling or contesting
any Tax Controversy involving a Tax Return for which it has filing responsibility under this Agreement. AgeX shall have full responsibility
and discretion in handling, settling or contesting any Tax Controversy involving a Tax Return for which it has filing responsibility
under this Agreement. Except as otherwise provided in Section 5.12(a)(i) hereof and in this Article VI, any costs incurred in
handling, settling or contesting any Tax Controversy shall be borne by the Party having full responsibility and discretion thereof.

 

(c)
In the event that (x) a statutory notice of deficiency (or foreign, state or local law equivalent) is received by BioTime from
the IRS or any other Tax Authority, (y) such notice is with respect to a Tax Return for which BioTime has filing responsibility
under this Agreement and (z) such notice relates in whole or in part to Restructuring Taxes for which AgeX could be liable to
BioTime pursuant to Section 5.12(a) hereof (a “AgeX Restructuring Issue”) then

 

(i)
BioTime, upon receiving a written request from AgeX to file a petition with the United States Tax Court (or equivalent foreign,
state or local court) seeking a redetermination of such deficiency, which shall be given no later than a date reasonably necessary
to permit preparation and timely filing of such petition, shall timely file such petition; provided, however, that, notwithstanding
such request, BioTime, with the prior written consent of AgeX, shall have the option to pay the amount of the deficiency, in which
case AgeX shall either itself pay or loan to BioTime no later than three (3) business days before BioTime pays such deficiency,
without interest, and, until a Final Determination of the AgeX Restructuring Issue results, one hundred (100) percent of the amount
of the portion of the deficiency relating to the AgeX Restructuring Issue, and to file a claim for the refund thereof, and, if
the claim is denied, to bring an action in a court of competent jurisdiction seeking the refund of Tax paid with respect to such
deficiency; or

 

    	 	18	 

     

    

 

(ii)
If (1) AgeX does not request BioTime to file a petition in the United States Tax Court (or equivalent foreign, state or local
court) for redetermination of the deficiency pursuant to Section 6.01(c)(i) hereof, (2) BioTime does not, on its own initiative,
timely file such a petition, and (3) AgeX requests that BioTime file a claim for refund, then AgeX shall either pay the deficiency
or request in writing that BioTime pay such deficiency, in which case AgeX shall loan to BioTime no later than three (3) business
days before BioTime pays such deficiency, without interest, and, until a Final Determination of the AgeX Restructuring Issue results,
one hundred (100) percent of the amount of the portion of the deficiency relating to the AgeX Restructuring Issue, which loan
BioTime shall use to pay such deficiency, and BioTime shall file a claim for refund thereof and, if the claim is denied, bring
an action in a court of competent jurisdiction seeking such refund.

 

(iii)
In the event that a judgment of the United States Tax Court or other court of competent jurisdiction results in an adverse determination
with respect to the AgeX Restructuring Issue, and BioTime notifies AgeX that it does not intend to appeal such AgeX Restructuring
Issue, then AgeX shall have the right to cause BioTime to appeal from such adverse determination at AgeX’s expense.

 

(iv)
AgeX and its representatives, at AgeX’s expense, shall be entitled to participate in (1) all conferences, meetings, or proceedings
with any Tax Authority, the subject matter of which is or includes the AgeX Restructuring Issue and (2) all appearances before
any court, the subject matter of which includes the AgeX Restructuring Issue.

 

(d)
The right to participate referred to in Section 6.01(c)(iv) hereof shall include, with respect to the AgeX Restructuring Issue,
the right to participate in the preparation and submission of documentation, protests, memoranda of fact and law and briefs; the
conduct of oral arguments or presentations; the selection of witnesses; and the negotiation of stipulations of fact.

 

(e)
Notwithstanding Sections 6.01(c)(iv) and (d) hereof, unless and until the notice provided in Section 6.01(c)(iii) above is given,
BioTime shall control the litigation of the AgeX Restructuring Issue and have the authority to settle in a reasonable manner and
in good faith any such issue.

 

Section
6.02 Cooperation and Exchange of Information.

 

(a)
Each Party shall cooperate fully at such time and to the extent reasonably requested by the other Party in connection with the
preparation and filing of any Tax Return or claim for refund, or the conduct of any audit, dispute, proceeding, suit or action
concerning any issues or other matters considered in this Agreement. Such cooperation shall include, without limitation, the following:
(i) forwarding promptly copies of appropriate notices and forms or other communications received from any Tax Authority (including
any IRS revenue agent’s report or similar report, notice of proposed adjustment, or notice of deficiency) or sent to any
Tax Authority or any other administrative, judicial or other governmental authority that relate to a Disputed Tax Issue; (ii)
the retention and provision on demand of Tax Returns, books, records (including those concerning ownership and Tax basis of property
which either Party may possess), documentation or other information relating to the Tax Returns, including accompanying schedules,
related workpapers, and documents relating to rulings or other determinations by Taxing Authorities, until the expiration of the
applicable statute of limitations (giving effect to any extension, waiver or mitigation thereof) subject to the provisions of
Section 6.02(e) hereof; (iii) the provision of additional information, including an explanation of material provided under clause
(i) of Section 6.02(a) hereof, to the extent such information is necessary or reasonably helpful in connection with the foregoing;
(iv) the execution of any document that may be necessary or reasonably helpful in connection with the filing of a Tax Return by
BioTime or AgeX or of their respective subsidiaries, or in connection with any audit, dispute, proceeding, suit or action; and
(v) such Party’s commercially reasonable efforts to obtain any documentation from a governmental authority or a third party
that may be necessary or reasonably helpful in connection with any of the foregoing.

 

    	 	19	 

     

    

 

(b)
Both Parties shall use reasonable efforts to keep each other advised as to the status of Tax audits or Tax Controversies involving
a Disputed Tax Issue and cooperate in a defense with respect to a Disputed Tax Issue in any Tax Controversy.

 

(c)
Each Party shall make its employees and facilities available on a reasonable and mutually convenient basis in connection with
any of the foregoing matters.

 

(d)
If either Party fails to provide any information requested pursuant to Section 6.02 hereof within a reasonable period, as determined
in good faith by the Party requesting the information, then the requesting Party shall have the right to engage a public accounting
firm to gather such information, provided that thirty (30) days prior written notice is given to the unresponsive Party. If the
unresponsive Party fails to provide the requested information within thirty (30) days of receipt of such notice, then such unresponsive
Party shall permit the requesting Party’s public accounting firm full access to all appropriate records or other information
as reasonably necessary to comply with the requirements of Section 6.02 hereof and shall reimburse the requesting Party or pay
directly all costs connected with the requesting Party’s engagement of the public accounting firm.

 

(e)
Upon the expiration of any statute of limitations, the documentation of BioTime or AgeX or any of their respective subsidiaries,
including, without limitation, books, records, Tax Returns and all supporting schedules and information relating thereto, shall
not be destroyed or disposed of unless (i) the Party proposing such destruction or disposal provides sixty (60) days prior written
notice to the other Party describing in reasonable detail the documentation to be destroyed or disposed of and (ii) the recipient
of such notice agrees in writing to such destruction or disposal. If the recipient of such notice objects, then the Party proposing
the destruction or disposal shall promptly deliver such materials to the objecting Party at the expense of the objecting Party.

 

Section
6.03 Reliance on Exchanged Information. If either Party supplies information to the other
Party upon such Party’s request, and an officer of the requesting Party intends to sign a statement or other document under
penalties of perjury in reliance upon the accuracy of such information, then a duly authorized officer of the Party supplying
such information shall certify, to the best of such Party’s knowledge, the accuracy and completeness of the information
so supplied.

 

    	 	20	 

     

    

 

Section
6.04 Payment of Tax and Indemnity. BioTime shall timely pay (or shall cause to be timely
paid) all Taxes of the Consolidated Group, of any Combined Group which includes a member of the BioTime Group and of any entity
or person that is not a member of the AgeX Group and shall indemnify and hold harmless AgeX for all liability for Taxes of any
member of the Consolidated Group, of any Combined Group which includes a member of the BioTime Group or of any other person or
entity that is not a member of the AgeX Group assessed against any member of the AgeX Group pursuant to Treasury Regulations §
1.1502-6 or any analogous or similar law.

 

ARTICLE
VII.

WARRANTIES
AND REPRESENTATIONS

 

Section
7.01 Warranties and Representations Relating to Actions of BioTime and AgeX. Each of BioTime
and AgeX warrants and represents to the other that:

 

(a)
it is a corporation duly organized, validly existing and in good standing under the laws of the state of its incorporation and
has all requisite corporate power to own, lease and operate its properties, to carry on its business as presently conducted and
to carry out the transactions contemplated by this Agreement;

 

(b)
it has duly and validly taken all corporate action necessary to authorize the execution, delivery and performance of this Agreement
and the consummation of the transactions contemplated hereby;

 

(c)
this Agreement has been duly executed and delivered by it and constitutes its legal, valid and binding obligation enforceable
in accordance with its terms subject, as to the enforcement of remedies, to (i) applicable bankruptcy, reorganization, insolvency,
moratorium or other similar laws affecting the enforcement or creditors’ rights generally from time to time in effect and
(ii) to general principles of equity, whether enforcement is sought in a proceeding at law or in equity; and

 

(d)
the execution and delivery of this Agreement, the consummation of the transactions contemplated hereby, or the compliance with
any of the provisions of this Agreement will not (i) conflict with or result in a breach of any provision of its certificate of
incorporation or by-laws, (ii) breach, violate or result in a default under any of the terms of any agreement or other instrument
or obligation to which it is a party or by which it or any of its properties or assets may be bound, or (iii) violate any order,
writ, injunction, decree, statute, rule or regulation applicable to it or affecting any of its properties or assets.

 

Section
7.02 Warranties and Representations Relating to the Distribution.

 

(a)
In General. Each of the Parties represents that, as of the date of this Agreement, it knows of no fact (after due inquiry)
that may cause the Tax treatment of the Distribution to be other than a distribution of AgeX stock with respect to which no gain
or loss is recognized by BioTime, AgeX or their respective stockholders pursuant to Section 355 and related provisions of the
Code and relevant Treasury regulations promulgated thereunder (such distribution a “Tax Free Spinoff”).

 

    	 	21	 

     

    

 

(b)
No Contrary Plan. Each of the Parties represents that it has no plan or intent to take any action which is inconsistent
with the treatment of the Distribution as a Tax Free Spinoff.

 

(c)
Subsequent Agreement. Each of the Parties agrees that if BioTime’s Board of Directors determines to effect the Distribution,
the Parties will enter into an amendment of this Agreement or a separate agreement containing customary obligations of the Parties
intended to qualify and maintain the Distribution as a Tax Free Spinoff.

 

Section
7.03 Tax Records. The Parties to this Agreement hereby agree to retain and provide on proper
demand by any Tax Authority (subject to any applicable privileges) the books, records, documentation and other information relating
to any Tax Return until the later of (a) the expiration of the applicable statute of limitations (giving effect to any extension,
waiver or mitigation thereof), (b) the date specified in an applicable records retention agreement entered into with the IRS,
(c) a Final Determination made with respect to such Tax Return and (d) the final resolution of any claim made under this Agreement
for which such information is relevant. Notwithstanding the prior sentence, no Party may destroy any such records without the
approval of all other Parties to this Agreement as described in section 6.02 hereof. 

 

ARTICLE
VIII.

MISCELLANEOUS PROVISIONS

 

Section
8.01 Notice. Any notice, demand, claim, or other communication required or permitted to be given under this Agreement (a
“Notice”) shall be in writing and may be delivered by (i) personal service, provided a receipt is obtained therefor,
(ii) certified mail, return receipt requested, postage prepaid, (iii) next business day delivery service, (iv) telecopier, or
(v) email, with acknowledgment of receipt requested, to the either of the Parties at the following addresses (or at such other
address as one Party may specify by notice to the other Party):

 

    	 	22	 

     

    

 

BioTime
at:

 

BioTime,
Inc.

1010
Atlantic Avenue, Suite 102

Alameda,
California 94501

Attn:
Aditya Mohanty, Co-CEO

E-mail:
amohanty@biotimeinc.com

 

and
to:

 

BioTime,
Inc.

1010
Atlantic Avenue, Suite 201

Alameda,
California 94501

Attn:
General Counsel

E-mail:
legal@biotimeinc.com

 

AgeX
at:

AgeX
Therapeutics, Inc.

1010
Atlantic Avenue, Suite 201

Alameda,
California 94501

United
States

Attn:
Michael D. West, CEO

 

A
Notice which is delivered personally shall be deemed given as of the date specified on the written receipt therefor. A Notice
mailed as provided herein shall be deemed given on the third business day following the date so mailed. A notice delivered by
next business day delivery service shall be deemed given on the first business day after deposit with the delivery service unless
a signed receipt of delivery indicates delivery on a later date. A Notice delivered by telecopier or email shall be deemed given
upon the date it is transmitted provided that such transmission is not later than 5:00 p.m. on a regular business day, or the
next business day if transmitted after 5:00 p.m. or on a day other than a regular business day. Notification of a change of address
may be given by either Party to the other in the manner provided in Section 8.01 hereof for providing a Notice.

 

Section
8.02 Injunctions. The Parties acknowledge that irreparable damage would occur in the event
that any of the provisions of this Agreement were not performed in accordance with its specific terms or were otherwise breached.
The Parties hereto shall be entitled to an injunction or injunctions to prevent breaches of the provisions of this Agreement and
to enforce specifically the terms and provisions of this Agreement and to enforce specifically the terms and provisions hereof
in any court having jurisdiction, such remedy being in addition to any other remedy to which they may be entitled at law or in
equity.

 

    	 	23	 

     

    

 

Section
8.03 Further Assurances. Subject to the provisions hereof,
the Parties hereto shall make, execute, acknowledge and deliver such other instruments and documents, and take all such other
actions, as may be reasonably required in order to effectuate the purposes of this Agreement and to consummate the transactions
contemplated hereby. Subject to the provisions hereof, each of the Parties shall, in connection with entering into this Agreement,
perform its obligations hereunder and take any and all actions relating hereto, comply with all applicable laws, regulations,
orders, and decrees, obtain all required consents and approvals and make all required filings with any governmental agency, other
regulatory or administrative agency, commission or similar authority and promptly provide the other Party with all such information
as such Party may reasonably request in order to be able to comply with the provisions of this sentence.

 

Section
8.04 Parties in Interest. Except as herein otherwise specifically provided with respect to
Indemnified Parties, nothing in this Agreement expressed or implied is intended to confer any right or benefit upon any person,
firm or corporation other than the Parties and their respective successors and assigns.

 

Section
8.05 Setoff. All payments to be made under this Agreement shall be made without setoff, counterclaim
or withholding, all of which are expressly waived.

 

Section
8.06 Change of Law. If, due to any change in applicable law or regulations or the interpretation thereof by any court of
law or other governing body having jurisdiction subsequent to the date of this Agreement, performance of any provision of this
Agreement or any transaction contemplated thereby shall become impracticable or impossible, the Parties hereto shall use their
best efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such provision.

 

Section
8.07 Termination and Survival. Notwithstanding anything in this Agreement to the contrary, this Agreement shall remain
in effect and its provisions shall survive for the full period of all applicable statutes of limitation (giving effect to any
extension, waiver or mitigation thereof) or until otherwise agreed to in writing by BioTime and AgeX, or their successors.

 

Section
8.08 Amendments; No Waivers.

 

(a)
Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in
the case of an amendment, by BioTime and AgeX, or in the case of a waiver, by the Party against whom the waiver is to be effective.

 

(b)
No failure or delay by any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power
or privilege.

 

Section
8.09 Governing Law and Interpretation. This Agreement shall be governed by and construed in accordance with the laws of
the State of Delaware applicable to agreements made and to be performed in the State of Delaware.

 

    	 	24	 

     

    

 

Section
8.10 Resolution of Certain Disputes. Any disagreement between the Parties with respect to any matter that is the subject
of this Agreement, which is not resolved by mutual agreement of the Parties, shall be resolved by a nationally recognized independent
accounting firm chosen by and mutually acceptable to the Parties hereto (an “Accounting Referee”). Such Accounting
Referee shall be chosen by the Parties within fifteen (15) business days from the date on which one Party serves written notice
on the other Party requesting the appointment of an Accounting Referee, provided that such notice specifically describes the calculations
to be considered and resolved by the Accounting Referee. In the event the Parties cannot agree on the selection of an Accounting
Referee, then the Accounting Referee shall be any office or branch of the public accounting firm of BDO The Accounting Referee
shall resolve any such disagreements as specified in the notice within thirty (30) days of appointment; provided, however, that
no Party shall be required to deliver any document or take any other action pursuant to this Section 8.10 if it determines that
such action would result in the waiver of any legal privilege or any detriment to its business. Any resolution of an issue submitted
to the Accounting Referee shall be final and binding on the Parties hereto without further recourse. The Parties shall share the
costs and fees of the Accounting Referee equally.

 

Section
8.11 Confidentiality. Except to the extent required to protect a Party’s interests in a Tax Controversy, each Party
shall hold and shall cause its consultants and advisors to hold in strict confidence, unless a Party determines in good faith
that such disclosure is required pursuant to any Federal or state securities law or regulations thereunder, or compelled to disclose
by judicial or administrative process or, in the opinion of its counsel, by other requirements of law, all information (other
than any such information relating solely to the business or affairs of such Party) concerning the other Party or its representatives
pursuant to this Agreement (except to the extent that such information can be shown to have been (i) previously known by the Party
to which it was furnished, (ii) in the public domain through no fault of such Party, or (iii) later lawfully acquired from other
sources by the Party to which it was furnished), and each Party shall not release or disclose such information to any other person,
except its auditors, attorneys, financial advisors, bankers and other consultants, advisors, and potential investors, lenders
or acquirers who shall be advised of the provisions of this Agreement and who, in the case of potential investors, lender, or
acquirers, have agreed in writing (subject to customary terms and conditions) to keep such information confidential. Each Party
shall be deemed to have satisfied its obligation to hold confidential information concerning or supplied by the other Party if
it exercises the same care as it takes to preserve confidentiality for its own similar information.

 

Section
8.12 Costs, Expenses and Attorneys’ Fees. Except as expressly set forth in this Agreement, each Party shall bear
its own costs and expenses incurred pursuant to this Agreement. In the event either Party to this Agreement brings an action or
proceeding for the breach or enforcement of this Agreement, the prevailing party in such action, proceeding, or appeal, whether
or not such action, proceeding or appeal proceeds to final judgment, shall be entitled to recover as an element of its costs,
and not as damages, such reasonable attorneys’ fees as may be awarded in the action, proceeding or appeal in addition to
whatever other relief the prevailing party may be entitled. For purposes of this Section 8.12, the “prevailing party”
shall be the Party who is entitled to recover its costs; a Party not entitled to recover its costs shall not recover attorneys’
fees. No sum for attorneys’ fees shall be counted in calculating the amount of the judgment for purposes of determining
whether a Party is entitled to recover its costs or attorneys’ fees.

 

Section
8.13 Counterparts. This Agreement may be executed in one or more counterparts, each of which
shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

 

    	 	25	 

     

    

 

Section
8.14 Severability. The Parties hereby agree that, if any provision of this Agreement should
be adjudicated to be invalid or unenforceable, such provision shall be deemed deleted herefrom with respect. All other remaining
provisions of this Agreement shall remain in full force and effect.

 

Section
8.15 Entire Agreement; Termination of Prior Agreements.

 

(a)
This Agreement contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes all
other agreements, whether or not written, in respect of any Tax between or among any member or members of the BioTime Group, on
the one hand, and any member or members of the AgeX Group, on the other hand. Any such other agreements are hereby canceled and
any rights or obligations existing thereunder are hereby fully and finally settled without any payment by any party thereto.

 

(b)
Without limiting the foregoing, the Parties acknowledge and agree that in the event of any conflict or inconsistency between the
provisions of this Agreement and the provisions of the Asset Contribution Agreement, the provisions of this Agreement shall take
precedence and to such extent shall be deemed to supersede such conflicting provisions under the Asset Contribution Agreement.

 

Section
8.16 Assignment. This Agreement is being entered into by BioTime and AgeX on behalf of themselves
and each member of the BioTime Group and AgeX Group, respectively. This Agreement shall constitute a direct obligation of each
such member and shall be deemed to have been readopted and affirmed on behalf of any corporation which becomes a member of the
BioTime Group or AgeX Group in the future. BioTime and AgeX hereby guarantee the performance of all actions, agreements and obligations
provided for under this Agreement of each member of the BioTime Group and AgeX Group, respectively. BioTime and AgeX shall, upon
the written request of the other, cause any of their respective group members to formally execute this Agreement. This Agreement
shall be binding upon, and shall inure to the benefit of, the successors, assigns and persons controlling any of the corporations
bound hereby for so long as such successors, assigns or controlling persons are members of the BioTime Group or the AgeX Group
or their successors and assigns.

 

Section
8.17 Fair Meaning. This Agreement shall be construed in accordance with its fair meaning and shall not be construed strictly
against the drafter.

 

Section
8.18 Commencement. This Agreement shall commence on the date of execution indicated below.

 

Section
8.19 Titles and Headings. Titles and headings to sections herein are inserted for the convenience
of reference only and are not intended to be a part or to affect the meaning or interpretation of this Agreement.

 

Section
8.20 Construction. In this Agreement, unless the context otherwise requires the terms “herein,”
“hereof,” and “hereunder” refer to this Agreement.

 

Section
8.21 Termination. This Agreement may be terminated at any time prior to the date of the Distribution, without the approval
of AgeX, by and in the sole discretion of the BioTime Board of Directors. In the event of such termination, no Party shall have
any liability to the other Party from or for the terminated Agreement; provided that any agreement that remained in force prior
to the Deconsolidation Date, shall remain in force upon a termination of this Agreement pursuant to this Section 8.21.

 

    	 	26	 

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement as of the day and year first above written.

 

	 	BioTime
    Inc.
	 	 	 
	 	By:	/s/
    Aditya Mohanty
	 	Name:	Aditya
    Mohanty
	 	Title:	Co-Chief
    Executive Officer
	 	 	
	 	AgeX
    Therapeutics, Inc.
	 	 	 
	 	By:	/s/
    Michael D. West
	 	Name:	Michael
    D. West
	 	Title:	Chief
    Executive Officer

 

    	 	27	 

     

    

 

EXHIBIT
A

 

Entities
Comprising the BioTime Group

 

	BioTime
                                         Domestic Subsidiaries

        

        

        
	 	BioTime
                                         Foreign Subsidiaries

        

        

        

        

	 	 	 
	OrthoCyte
    Corporation	 	Cell Cure Neurosciences,
    Ltd
	LifeMap
    Solutions, Inc.	 	ES Cell International
    Pte Ltd

 

    	 

     

    

 

EXHIBIT
B

 

Entities
Comprising the AgeX Group

 

	AgeX
                                         Domestic Subsidiaries

        

        

        

        

        
	 	AgeX
                                         Foreign Subsidiaries

        

        

	 	 	 
	LifeMap
    Sciences, Inc.	 	
	ReCyte
    Therapeutics, Inc.	 	LifeMap
    Sciences Ltd.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]